roche annual report business report innovate healthcareinnovative solution span healthcare spectrum combine capability diagnostic pharmaceutical enable meet need entire healthcare spectrum identify disease suscep tibilitie screen disease atrisk population prevention diagnosis therapy treatment monitor innovative product advance fight disease wide range front make real difference patient health professional roche commitment innovate healthcare match commitment corporate social responsibility sustainability company guide value recognise economic social environmental concern inter twine progress sector require progress researchintensive company longterm strategic focus roche strive deliver sustainable value major stakeholderspredisposition table content good know medication help business report key figure year brief letter chairman roche group early detection group result outlook not stand group strategy theuncertainty long pharmaceutical pharmaceutical division brief result therapeutic area research development prevention rd pipeline expand biotech production medication help capacity myosteoporosisand access medicine totake amonth diagnostic diagnostic division brief result business area diagnosis research development key product launch schedule suddenly realise life washange thread access diagnostic board director corporate executive committee corporate governance board director corporate executive committee therapy page corporate governance responsible feeling regain sustainable management control disease give ahuge psychological lift dialogue stakeholder commitment employee commitment society monitor safety health ve get independence environmental protection assurance track record outlook key performance indicator gri reference list roche global market presence business report key figure roche group change mchf mchf chf lc sale sale research development operating profit exceptional item net income net cash equity change equity ratio core earning share chf dividend sharein chf number employee dec continue business propose board director lc local currency price development nonvoting equ ity security genussschein chf roche nonvoting equity security adjust swiss market index rebase business report year brief group roche group increase sale billion swiss franc record high billion swiss franc operating profit margin percentage point net income virtually level year despite income billion swiss franc divest consumer health business group award credit rating aa standard poor aa moodys roche reselecte inclusion dow jones sustainability indexes board propose th consecutive dividend increase swiss franc share nonvoting equity security pharmaceutical pharmaceutical sale advance time global market growth rate sale anticancer drug billion swiss franc strengthen roche market leadership oncology tamiflu production expand significantly meet huge need pandemic readiness supply positive result phase iii clinical trial rheumatoid arthritis breast lung pancreatic cancer diagnostic roche diagnostic maintain global market leadership sale growth operating profit remain previous year record level margin slightly generation accuchek diabete management product launch worldwide outlook abovemarket sale growth doubledigit increase roche group pharmaceutical division core earning share growth target line sale growth visit httpwwwrochecom additional information roche growth rate base local currency operate profit margin state exceptional item business report letter chairman franz b humer verwaltungsratsprsident und ceo company outstanding innovative diagnostic division maintain leadership roche medicine diagnostic help advance position difficult marketbut fall slightly short fight disease operationally ofit performance goal financially group post strong result substantial market share gain group operating profit exceptional item significant improvement operating profitability rise onethird record high billion swiss general meeting shareholder board francsat billion swiss francsnet income come director propose dividend increase close matching previous year figuredespite swiss franc share nonvoting income billion swiss franc record equity securityifapprovedthis thegroup divest consumer health business nineteenth dividend increase year strong earning performance enable con tinue invest heavily research develop sale roche group rise local curren ment expand production basewith cie time exceed billion swiss group expenditure research development franc pharmaceutical division account total billion swiss franc annu increaseit sale allyour isone ofthe world researchinten yearfour time average market growth rate sive company year business report letter chairman additionally invest billion swiss increase prescription exist franc new biotech manufacturing facility drug year roche capture attention pace rise demand product health professional public exciting new clinical datathese include datum roche excellent financial health ing herceptin significant difference strengthen balance sheet signifi earlystage treatment aggressive breast cantly increase net cashover year cancer clinical trial involve nearly ratio equity total asset rise steadily woman add herceptin standard therapy increase financial strength halve risk ofcancer recurrence compare give strategic flexibility selectively expand standard therapy aloneand trial ofmabthera core pharmaceutical diagnostic busi rituxan lymphoma patient maintenance nessesin late standard poor moodys therapy drug show increase sur award roche credit rating aa aa vival dramatically tide respectively second high rating assign turn battle certain form agency disease claim like unthinkable year ago pharmaceutical division good year roche history despite expiry example illustrate drug research patent rocephin roche topselle development stop soon medicinethe division increase sale truly drug approve indicationtake impressive billion swiss franc billion development ofanticancer drug new level swiss franc time seven roche core mission global research medicine generate annual sale organisation billion swiss franc case signifi cantly morethe division operate profit margin significant progress project exceptional item show sig develop novel biotherapeutic rheumatoid arthri nificant improvement advance tisa common disease characterise progressive inflammation case progressive destruction joint clinical trial datum powerful oncology portfolio key driver confirm topselle anticancer medi superb result roche cine mabtherarituxan offer completely new healthcare company medicine cancer approach treat rheumatoid arthritis market show increase product develop chugai sub patient survival space division show clinical trial yearsa new generation ofmore targetedless toxic slow joint damage significantly dramatically anticancer medicine roche global improve disease painfuldisable symptom market leader oncology reinforce chance good believe roche leadership year sale growth soon major player disease area innovative new addition oncology portfolio avastin colorectal cancer tarceva lung respond threat potential flu pan cancer establish demic year great challenge roche act energetically responsibly new roche medicine launch success meet increase global demand lead fully therapeutic areasand supplemental influenza drug tamiflu step approval new indication spur significant promptly initiate massive scaleup pro business report letter chairman duction capacity risk adopt dna microarray test doctor gauge pricing policy provide significant discount patient ability metabolise certain drug base delivery ofthe drug pandemic useand patient genetic profile information give million pack oftamiflu help guide drug selection dose deci world health organization rapid response sionsadditional dna microarray testsfor cancer stockpile use epicentre ofa potential pan screeningare currently latestage development demic help establish regional stockpile druginadditionwe grant sub reflect group strong performance licence production drug pandemic create new job yearbringe total use hold indepth talk dozen number roche employee worldwide company provide additional manufac like opportunity ture support ifnecessary express thank people dedi cation professionalism value create roche diagnostic year focus working day vital ifroche continue launch new product particularly diabetes invest develop innovative solution area managementand year ofunmet medical needby help patient division expand market care effectiveand costefficient compete notably dna sequencingwhile clinically differentiate medicine diag market condition continue difficult roche nostic play increasingly important role diagnostic maintain lead market posi ease pressure healthcare budget tionwith sale advance local currency billion swiss franc division immuno decade roche actively commit diagnostic molecular diagnostic portfolio socially environmentally sustainable develop main growth driver menta deliver longterm benefit patientsat end year roche diagnostic post operating profit reselecte inclusion dow jones sustain billion swiss franc exceptional item ability index ftsegood indexwe matching alltime high previous year rank second pharmaceutical industry divisional profitability remain high category tribute sustainability industrydespite slight decrease operating effort please profit marginto strong pricing pressure equally please highly respected production startup cost cost relate publication include fortune science new product launch year include list good company main reason decline work global market leaderwe feel obli roche striven responsible cor gation supply advanced diagnostic porate citizen healthcare innovator significant contribution effective costefficient action take ensure availability patient care new generation accuchek tamiflu event pandemic recent product improve diabetes management example ofhow seriously wide respon begin launch worldwide ini sibilitie companywe set high standard perfect case point response policy practice trans strong tothe european launch ofour parency clinical researchwe disclose negative amplichip cyp test product take positive result latestage trial step close personalised medicineusing early year begin publish datum business report letter chairman clinical trial internetin addi tion roche establish independently host publicly accessible online trial protocol registry provide information clearsimple language commitment corporate social responsibility extend world develop coun triesours company research hivaidsand ofthe company supply medicine cost enforce patent right poor develop countriesin additionin early announce provide technical expertise manufacture aids drug saquinavir inter este manufacturer develop country cost clearly great contribution sustainability continue develop new well solution unmet medical need recognise continued viability suc cess innovative company depend business socially environmentally respon sible way outlook remain positive thank portfolio innovative product position continue create value expect division achieve abovemarket sale growth local currenciesand target core earning share rise line group sale franz bhumer business report good know medication help business report novel test bring personalise medicine close british scientist anneke westra diagnose manic depression start tenyear nightmare doctor prescribe succession drug adverse reaction cause hallucination blackoutsthough anneke fighting depression life not let stop earn phd biotech nology register patent giving lecture world medicine leave feel drain wear point attempt suicide obviously thing not like anneke begin investigate ownthat find amplichip cyp test test predict people ability metabolise certain drug anneke case test show body break clearing medicine slowly allow accumulate harmfully high level anneke lose year test result enable doctor adjust medication dosage work anneke treat lowdose combination medicine finally feel fine predisposition cytochrome p genes code drugmetabolising enzyme find primarily liver amplichip cyp test detect variation gene patient poor rapid metaboliser widely prescribe drug infor mation help physician well personalise drug selection dosing decision patient mean effective treatment few effect business report roche group group result operating activity taxis increase billion swiss franc roche group post strong operating result group sale increase significantly net financial income show significant improve billion swiss francsa gain local ment year thank group strong currency swiss franc dollar positive cash flow restructuring group pharmaceutical division key growth debt carry cut recent year driver sale increase time fast roche post positive financial result theglobal market average significantly ahead net income financial asset foreign growth rate north america europe exchange management exceeding financing cost japanthe division important market million swiss franc diagnostic division sale local currency increase line global market growth billion swiss francsgroup net income nearly high year billion swiss strong topline growth positive impact franc despite income billion swiss franc group earning performance divest consumer health business operating profit exceptional item rise group return sale margin local currency billion swiss francsand correspond operating profit margin improve significant improvement substantiallyrise percentage point group financial positionthe ratio equity excellent sale growth year total asset total offset significantly increase investment asset finance longterm launch prelaunch activity group strong development pipeline time theoperate result restate prior outlook year figure include cost group equity compensation plan employee bar unforeseen eventsroche reaffirm posi record operating expense group tive outlook sale pharmaceu improve earning performance primarily reflect tical diagnostic division expect pharmaceutical division significantly higher grow ahead ofthe market local currenciesand operate profit margin anticipate continue doubledigit growth pharmaceutical division group diagnostic division operate profit exceptional item decrease local currency sale growth expect strong billion swiss franc result margin second halfofthe year firstthe reason decline percentage point include patent expiry rocephin primarily heavy price pressure market copegus fact expand produc startup cost new manufacturing facilitiesthe tion capacity tamiflu result increase new product launch year delivery pandemic supply drug high depreciation increase volume second halfofour target core earning instrument placement share nonvoting equity security grow line sale despite significant investment group strong profitability reflect launch new product major new key figure ebitda rise local cur indication establish product rencie billion swiss francsand cash flow business report roche group group strategy pharmaceutical diagnostic business include majority shareholding genentech healthcare st century chugai hub roche innovation network diagnostic evolve consumer need innovation market pharmaceutical company capitalise dynamic likely key driver change broad synergies research development healthcare year aheaddespite enormous marketing capability augment progress fight diseasethere technology collaboration constellation area high unmet medical needand alliance develop individual product demand new well healthcare product product portfolio andservice bind grow result ofpopula tion age demographic change biotechnology important factor inno advance occur science technol vation strategy thank early involvement ogy recent year clearly implication major investment sectorbiologic cur clinical practiceraise hope day rently account approximately half roche well treatment mankind revenuesthe group own significant proportion disease way prevent ofthe world biotechnology manufacture capac cure thembut demand healthcare grow ity world lead producer pressure control costswhich therapeutic protein monoclonal antibodie unintended effect hamper innova tion create value today tomorrow distinctive strategy business model focus create sustain able value stakeholdersnot roche major divestment shareholder patient employee yearsmost recently sale ofthe consumer health society largewe currently develop businesshave aim focus group framework measuring value create energy entirely innovationintensive ofthese constituenciesand expect divisionspharmaceutical diagnosticstoday place time annual report roche highly focused companyand result position industry pioneer healthcare predisposition testing prevention diagnosis therapy treatment monitoringroche market leader oncology transplantation virology world leader vitro diagnostic roche aspire distinctive ability drive value creation discoverydevelopment commercialisation medically differentiate product specifically roche pursue industry leadership emerge field ofperson alise healthcare gain importance advance area genetic profiling enableearli diagnosis facilitate well patient stratification clinical eco nomic benefit preventive therapy target medicine appeal consumer payer regulator business report roche group create value stakeholder innovative innovation word work awfully hard everybodys innovator william burns ceo division roche pharmaceu nowadays claim tical heino von prondzynski ceo division william burn idea innovation roche diagnostic erich hunziker cfo healthcare centre patientto genuine talk roche strategy implemen advancea new medicine diagnostic meet tation patient need well s available certainly costconscious time witness mount pressure control payer need address healthcare spend company believe need payersand healthcare hurt safety concern highprofile prod system meet effectively uct healthcare sector experience address patientsneedsat roche pharmaceuti slowdown growth roche sale contrast cal use phrase clinically differentiate continued grow strongly com medicineto describe drug treat particular pany premium stock market rating patient population significantly higher make roche different degree success few effect erich hunziker roche strategy design optionsor simply easy takewe help excel todays costconscious healthcare anticancer medicine prove extend market market leader highgrowth patientslive claim healthcare com area like oncology transplantation hepatitis pany match exactly kind world leader vitro diagnosticsour aim product supply innovative prescription drug diag nostics bestinclass heino von prondzynski roche supply pioneer develop metoo drug offer marginal benefit e diagnostic device wide range use s marketand predisposition screen early detection interest follow competitor response monitor prognostic testing generic businessalsoinvestor contribute well medical deci increasingly riskaversewhich mean pay sionmake right line help doctor e close attention procedure company well decision fast virtually stage place risk management sustainabil fight disease promote ity include area like corporate governance meaningful saving time substan patentsaccess product poorest develop tially improve patient outcome ing country ethic businessthank sound policy procedure transparent leader major segment like report roche come recognise molecular diagnostic diabetes monitor leader corporate sustainability pioneer work biomarker cancer heart attack eh different way degree ofaspire innovatorat roche ve embrace inno vation greatest strengththe core ofour com petitive advantage ve innovation model place s like industry innovator obviously access cuttingedge science technologywe get biotechnology early onacquire major ity stake genentech potential protein thera peutic end business report roche group technological advance certainly major driver innovation role biotechnology play innovation process roche wmb understand ofthe molecular basis ofdisease growsit increasingly clear disease like cancerand diabetesare far diverse suspect sound like discourage newsit fact cause hopebecause mean likelihood ofiden tifying optimal molecular target new drug increase biotechnology open com pletely new therapeutic approachesparticularly oncology pursue new possibility aggressively confident william burns ceo division roche pharmaceutical bea major source offuture innovation course means expect key growth driver not mean intend stop work new chemical therapeu tic meansour chance ofdevelope truly differentiate medicine great wmb twin focus pharmaceutical drug discovery effort include small molecule diagnostic continue serve protein future particularly give industry trend away size fit allproduct individu eh roche great strength ability alise therapeutic option trendi addin craft longterm strategy follow roche clearly leader clinically lead biotechnology result strategic document therapeutic benefit increasingly choice course count strength biotechnology year unique innovation model combin unique research network lead diagnos ing strong inhouse rdmajority shareholding tic rd major competitive advantage genentech chugai partnership score biotechs university give personalise medicine reality broad access technology spur innova hvp like distant vision year tionwere major player biotechnology ago come reachroche poise strong launch world commercially available pharmacogenomic test amplichip cyp strategic rationale roche test help physician select medicine commitment diagnostic industry dosage suitable patientsone ofthe clearly dynamic pharmaceutical key technology power test poly hvp right roche diagnostic fore merase chain reactionor pcrfor shortthe ofanother revolution medicineour prod dna microarray develop uct helping address ofhealthcare microarraybase test diagnosis moni critical challengesnamelydrug safety efficacy tore cancer osteoporosis complex hand cost containment disease particularly oncology aim othera personalise medicine come age enable treatment tailor closely certainly roche combine expertise genetic profile ofspecific patient populationsour diagnostic therapeutic play key role leukemia microarrayfor examplewill major inpioneere new medical breakthrough step forward discriminate leukemia subtype quickly reliablyand amplichip p test day help physician reliably business report roche group focus highend medical innovation commercially risky give huge investment involve inherent uncertainty rd roche counterbalance risk eh despite heavy investment rdproduction marketingthere guarantee success generally speak continue pursue conservative financial investment strategy help counterbalance commercial risk associate hightech operating busi ness wmb maintain right balance house external rd innovation network erich hunziker chief financial officer view kind ofrisk spreadingstrategy majority stake genentech chugai alliance partnership comple ment augment internal capability variety ofwaysamong thingsby reinforce corporate culture promote creativityand determine aggressive cancer decide course significantly enhance depth therapy work one will not quality development pipelinewhich important aspect risk managementwe need wmb division work continue refine structure skill biomarker year biomarker enable build manage innova potential increase understand tion network successfullywe need ensure drug efficacy safety heino indi capability recognise promising cat play increasingly significant emerge technology early role drug discovery development partnership governance structures instance currently collaborate continue preferred partner product colleague diagnostic biomarker technology alliance predict patient rheumatoid arthritis likely benefit treatment right roche enjoy strong operating mabtherarituxan actemra rheumatoid earning expect continue arthritis emerge area ofstrength roche propose cash give grow range treatment option priority rheumatoid arthritisit extremely useful eh repay debt increase net liquidity test predict different patient high list financial prioritiesand cer respond different drug personalise tainly ofour strong cash flow medicine mean develop target good balance sheet currently iswe want drugsat present pursue development betterwhich great flexi cancer drug adjuvant use aggressively bility strengthen core businessesand not palliative treatment long continue carefully select acquisition move extend patient live curing primarily strengthen group strategically cancersdespite recent advanceshoweverthe war gain access new technology s cancer stillunfortunatelyfar financial resource goal not max imise quarterly earning bethat trap ve manage avoid odd long development cycle business business report roche group hvp healthcare market change signifi cantly decade way fairly easy predictageing population pop ulation growth certain fuel demand healthcarewhile increase pressure contain costsand equally certain person alise medicine grow mainstream medical practiceten year want company consistently bring clinically differentiate product service marketand want acknowledge regu lator payer company steady eye deliver benefit justify cost distinctive combination strength give strategic edge enable develop novel heino von prondzynski ceo division roche diagnostic product service span entire health care spectrum believe m provement step healthcare process start predisposition screen early detection roche carry make significant contribution front wmb achieve ambition require continue strong financial commitment research development intention ofdoingworldclass research backbone ofour strategy ofcreating value innovationit enable deliver advance healthcare create superior value patient stakeholdersand mean especially close eye new emerge development science technology continue anticipate trend adjust refine strategy accord ingly end business report not stand uncertainty long business report test hiv spare parent month worry healthy baby word parent want hear birth child ruth colin webb differentthe british couple hivpositive daughter bornthere time webbs wait agonising month daughter birth find girl hivthat long take sensitive test time detect virus child body hivpositive mother like ruth webb huge effort birth healthy childrento reduce risk mothertochild transmission ruth take fortovase pregnancy low hiv blood doctor closely track viral load hiv monitoring test way know baby alright bear spare addi tional month anxious wait hiv dna test provide initial reassur ance week birth webbs girl test result enormous relief sarah anna seven year old hivnegative early diagnosis pcrbase test detect tiny amount hiv make possible diagnose infection long symptom appear resolve uncertainty perinatal hiv transmission hivpositive patient doctor critical timeadvantage fighting virus early therapy start well business report pharmaceutical division brief sale million chf operating profit exceptional item million chf include charge equity compensation plans number employee key figure change change millions chf chf local currency sale sale roche pharmaceutical genentech chugai ebitda operate profit research development exceptional item pharma executive committee january william burns ceo division roche pharmaceutical george c abercrombie north america jennifer allerton informatics eduard holdener development peter hug partner jonathan kc knowles research dominic moorhead finance control paul newtonsyms human resource charles sabbah strategic marketing pascal soriot claude schreiner western europe jan van koeveringe technical operation february march business report pharmaceutical result sale region pharmaceutical division record good result exceed high abovemarket growth previous year sale latin america year rise local currency swiss japan franc dollar billion swiss francsfour time fast global marketthe gain offset decline group topselle medicine rocephin europe follow expiry patent julyas north america growth drive primarily strong demand division flagship oncology port folionow boost innovative cancer treat italic growth rate ments avastin tarceva strong sale cellcept transplantation pegasys hepatitis b c antiinfluenza drug tamiflu therapeutic area government stockpile pan demic readiness programme contribute oncology growth division oncology transplantation virology franchise significantly outpace cancer ofthe main cause ofdeath indus respective market trialise country roche group forefront search well solution operating profit exceptional item increase patient physician important area againby billion swiss francsthe oper unmet medical needroche pioneer number ate profit margin exceptional item gain ofadvance cancer treatmentincluding target percentage point rise therapy mabtherarituxan herceptin avastin improvement achieve tarceva xeloda example roche despite high investment rd continue group innovative cancer treatment product launch activity andby comparison low gain product divestment thousand outstanding year ebitda total billion swiss franc forthe roche group oncology portfoliosale salescompare previous year oncology product grow account oncology portfolio mabtherarituxan herceptin avastin xeloda tarceva bondronat kytril furtulon neupogen neorecormon roferona neutrogin picibanil vesanoid state growth rate local currency business report pharmaceutical sale therapeutic area breast cancer common cancer woman worldwide million woman newly diagnose die disease year different type transplantation breast cancer knowledge tumour charac dermatology teristic essential determine appropriate metabolic disorder treatment herceptin trastuzumab design central nervous system specifically particularly aggressive type tumour herpositive account approx infectious disease imately breast cancer sale herceptin target treatment approve cardiovascular disease herpositive breast cancershowe impressive inflammatory disease gain key market strong growth bone disease europe drive extension virology treatment duration increase firstline penetration herceptin support anemia considerable grow body clinical datum oncology show product offer significant survival benefit advance early disease setting result strong datum report divisional salesall major brand con herceptin reimburse tribute result substantially country adjuvant early disease reinforce group position world lead set advance approval major ing provider ofcancer medication development activitiesoncologypsette new standard cancer treatment p patient nonhodgkin lymphoma nhl group storyp malignancy lymphatic system affect approximately million people worldwide skeletal complication include hypercalcemia claim estimate life yearsale bone lesion fracture associate mabtherarituxan rituximabfor treatment cancer follow rollout bondronat indolent aggressive form nhl ibandronic acid major european market strong yeardriven steady rise prevention skeletal event patient prescription form ofnhl europe breast cancer bone metastasessale increase august genentech biogen idec file sup stronglyby million swiss franc plemental application food drug administration fda approval product colorectal cancer cancer large intestine use untreated patient intermediate rectum account million new case grade aggressive nhl pivotal international newly diagnose cancer phase iii clinical trial show year worldwide yearit second mostcommon maintenance therapy mabtherarituxan cause cancer death europethe main treat dramatically improve chance survival ment surgerywhich combine patient suffer indolent nonhodgkin radiotherapy chemotherapy lymphoma regardless initial therapy base result roche file application avastin bevacizumab antiangiogenic eu regulator december expand drug treatment cancer generate product indication include maintenance treat impressive billion swiss franc sale ment patient indolent nhl major year marketalready approve development activity pp information treatment advance colorectal cancer ongoing clinical development programme avastin receive eu approval indica mabtherarituxan product tion january launch business report pharmaceutical oncology professional move asco oncology specialist professional attend st american society clinical oncology asco meeting orlando florida present jonas marque oncologyhematology sale manager roche brazil particularly interested special session avastin herceptin product feature pack session clearly move attendee consider study present extremely important impact consistent finding cancer colorectal currently await herceptin presentation world lead approval brazil oncologist remark biology speak listen add herceptin usher attendee respond stand ovation new era breast cancer treatment time see type datum presentation say jonas think say lot presentation impact evident se impact product cancer world sion say jonas brazilian specialist call clinic prescribe herceptin adjuvant therapy jona join roche brazil oncology team patient treat breast cancer aware importance month work patient care herceptin presentation asco meeting give job new meaning oncologist impress datum woman herpositive breast cancer avastin appear potential treatment real chance longterm survival key european marketssale continue europepancreatic cancerone rapid growthwhile uptake europe aggressive malignancy kill high proportion strongsee patient storyp ofpatient year diagnosis cancerit resistant chemotherapy sale xeloda capecitabine continue radiotherapy tend spread quickly strong upward trend impressive gain part body pancreatic cancer major market growth fuel fifth lead cause cancer death devel recent eu approval use ofthe prod ope world tenth frequent cancer uct adjuvant treatment surgery ofcolon europewhere kill people year cancer year market tarceva estimate million new case annually erlotinib novel target cancer drug lung cancer common cancer worldwide prove survival benefit advanced nonsmall cell leading cause ofcancer death world lung cancer pancreatic cancergenerate robust business report pharmaceutical salesmarket response product prove longterm organ patient survival positive follow approval late benefits zenapax daclizumab prevent second thirdline treatment nonsmall cell acute rejection newly transplant organ lung cancerthe product receive eu approval valcyte valganciclovir prevention indication september cytomegalovirus cmva dangerous infection launch european coun associate transplantation complete try rollout market schedule roche transplantation portfolio roche support november thefda approve basic transplantation research funding tarceva treatment advance pancreatic independent roche organ transplantation cancera filing indication submit research foundation eu regulators october roche group maintain global leadership anemia transplantation market group transplantation portfolio generate total sale anemia occur number ofre blood cell billion swiss franc rise fall normal starve organ tissue previous year immunosuppressant cellcept oxygen see patient post solid doubledigit gain globally impair renal function chronic kidney key region maintain leadership disease patient cancer mycophenolic acid market market share potential longterm effect anemia include despite entry ofa new competitor cardiovascular disease renal patient duce survival patient canceranemia valcytethe market leader prevention cmv fatal ifleft untreated disease show consistent growth year solid doubledigit gain record sale roche neorecormon chugais combine sale valcyte cymevene epogin epoetin betafor treatment ofanemia ganciclovir show healthy growth neorecormon retain leadership position market virology despite sustain pricing pressurewith indi cation cancerrelate anemia renal anemia liver bodys important contribute increase sale organ perform vital function oncology set neorecormon continue hepatitis b c viruse hbvhcv cause strong market penetrationposting growth acute chronic liver diseasepotentially lead ahead market thank primarily liver failure cirrhosis cancer worldwide continue adoption convenient million people think chronically weekly prefille syringe formulationneorecormon infect hbv highly infectious pathogen indicate treatment anemia responsible estimate million death patient solid lymphoid cancer receiv annuallymore million people ing form ofchemotherapy world infect hcvand million new case occur yearhepatitis c main reason transplantation liver transplantation people worldwide receive lifesave combine sale pegasys peginterferon alfaa organ transplant year thank advance copegus ribavirin show strong growth surgical procedure immunosuppressive particularhigher sale volume europe therapy prevent organ rejection transplant drive market share increase market recipient survive year expansion result ofnew indicationssignificant new organsthis mean increase demand approval end early effective lowtoxicity immunosuppressant drug give pegasys plus copegus combi like cellcept mycophenolate mofetil nation broad range ofhepatitis c indication business report pharmaceutical meet world demand tamiflu world health organization recom mend government stockpile antiviral preparation possible influenza pandemic overall pandemic plan roche assist government dramatically expand ing tamiflu production capacity respond critical need armin knoblich global supply chain leader tamiflu proud international task force roche specialist work clock ramp supply quickly able produce million treatment annually say extract star anise plant native expand network supplier thirdparty province china shikimic acid pro manufacturer licensee selectively invest duce large quantity special fermentation facility way meet demand method rely star anise expand tamiflu keeping manufacture network production shikimic acid fermentation roche flexible respond situation future help ensure tamiflu production hold crop failure disruption new production process play role supply example shikimic acid start material tamiflu product combination include use reserved use rapid response stockpile patient coinfecte hiv contain influenza pandemic outbreak roche normal liver enzyme level application continue substantially expand tamiflu pro approval ofcombine pegasys copegus hep duction capacity able produce atitis c chugai designate priority million treatment annually review japanese authority pegasys collaborative network ofit facility approve treatment hepatitis b ofa significant number ofindependent company country worldwide october roche announce willingness enter discussion government worldwide sale tamiflu oseltamivir rise manufacturer production tamiflu billion swis francsdriven severe influenza emergency pandemic use roche sign season japan early year increase sublicense agreement shanghai pharma orders pandemic readiness supply ceutical china hetero drug india country place order pandemic discussion additional partner stock tamiflu purchase enhance tamiflu production network cover population roche end year fda approve emea agree donate million pack oftamiflu swiss authority recommend approval world health organization product prevention influenza chil million pack keep regional stockpile dren aged year meet world demand use event outbreak avian influenza fortamifluaboveand access medicinesp andanother million pack central storage business report pharmaceutical major product approval launch product generic indication country avastin bevacizumab firstline treatment combination chemotherapy eu metastatic colorectal cancer bonvivaboniva ibandronic acid osteoporosis oral oncemonthly formulation eu usa switzerland osteoporosis intravenous formulation usa invirase saquinavir hiv disease mg formulation eu switzerland pegasys peginterferon alfaa chronic hepatitis b eu usa hcvhiv coinfection eu usa switzerland tarceva erlotinib second thirdline treatment advance eu nonsmall cell lung cancer switzerland advanced pancreatic cancer combination usa gemcitabine xeloda capecitabine adjuvant colon cancer monotherapy eu usa switzerland include supplemental indication update january hiv worldwide pandemicand number primary care people live hiv continue risethe world health organization estimate million osteoporosis cause gradual loss ofbone density people include million child make bone brittle prone breakit affect live hivaid end offor million people worldwide especially woman year roche innovative drug diag menopause nostic test place forefront ofeffort combat hiv infection aids bonvivaboniva ibandronic acid continue work improve standard hiv oncemonthly oral bisphosphonate approve care worldwide information roche treatment ofpostmenopausal osteoporosis hivaid initiativessee access medicinesp launch roche copromotion ensure access healthcare worldwide pand ner glaxosmithkline april visit wwwrochecom europe september sale total million swiss franc expect gain sale fuzeon enfuvirtide increase momentum physician patient recognise million swiss franc help datum prefer simplicity convenience major study show add value oncemonthly tabletin january boniva injec fuzeon prescribe late tion intravenous medication antihiv agent recent update key treatment approve treatment post guideline support fuzeon use treatment menopausal osteoporosis provide prove experienced patient expect drive bonestrengthene benefit bisphosphonate uptake ofthe drug therapy woman give month boniva injection design meet need ofpatient unable tolerate oral bisphosphonatesthe eu authority cur rently review marketing application innovative formulation bonviva patient storyp business report pharmaceutical topselle pharmaceutical product roche group sale change product generic indication millions chf local currency mabtherarituxan rituximab nonhodgkin lymphoma neorecormon epogin epoetin beta anemia herceptin trastuzumab metastatic breast cancer cellcept mycophenolate mofetil transplantation avastin bevacizumab metastatic colorectal cancer tamiflu oseltamivir treatment prevention influenza b pegasys peginterferon alfaa hepatitis b c rocephin ceftriaxone bacterial infection xeloda capecitabine colorectal breast cancer xenical orlistat weight loss weight control kytril granisetron nausea vomit induce chemotherapy radiation therapy follow surgery nutropin protropin somatropin somatrem growth hormone deficiency xolair omalizumab asthma copegus ribavirin hepatitis c cymevene valcyte ganciclovir valganciclovir cytomegalovirus infection pulmozyme dornase alfadnase cystic fibrosis tarceva erlotinib nonsmall cell lung cancer pancreatic cancer neutrogin lenograstim neutropenia associated chemotherapy dilatrend carvedilol chronic heart failure hypertension coronary artery disease activase tnkase alteplase tenecteplase myocardial infarction global sale xenical orlistat research development flat marketin product eu labeling expand include datum use ofthe product roche commit discover develop obese adolescent xenical ingclinically differentiate medicine key thera weightloss medication united states peutic area include oncology inflammatory europe information label autoimmune bone diseasesvirology trans february exist agreement glaxo plantation broad interdisciplinary approach smithkline expand include promotion possible combine expertise prescription xenical ofgsk sale group pharmaceutical diagnostic division forcesin january fda advisory committee helping expand understanding ofdisease recommend approval application file biological process translate scientific gsk june market lowdose orlistat advance innovative medicinesinnovation overthecounter medicine weight loss science technology core roche group focus rd strategy major product success strategy reflect rich expect sale rocephin ceftriaxone ness group pharmaceuticals pipeline decline markedly follow expiry ofthe prod strength express number ofnew uct patent july emergence ofgeneric molecular entity nmes rd portfolio competitor second halfofthe year success rate group latestage clinical business report pharmaceutical research project major therapeutic area expertise therapeutic antibody research december add newcuttingedge technology product roche rd organisation pipeline glycart unique protein technology complement oncology effort develop biological compound offer neurological patient superior efficacy safety psychiatric disease virology rd pipeline respiratory disease genitourinary disease end pharmaceutical division inflammatory autoimmune rd pipeline comprise project include bone disease new molecular entity nmes addi cardiovascular tional indication fourteen nme currently metabolic disease phase phase phase ii phase iii file regulatory reviewin project enter phase development enter phase ii enter phase iii seven project move ofthe rd portfolio follow regula tory approval roche pharmaceutical currently project trial offifteen phase iii trial preclinical research seven therapeutic meet clinical endpoint make roche area development project thera industry leaderthis selection deci peutic area sion base aggressive screening thorough profiling ofcompound discoverypreclinical rochemanaged rd project early clinical stage discontinue phase revert rd partner discontinue cornerstone ofour rd strategy empha phase revert rd partner sise value leverage key product asset outlicense discontinued expand use new indication phase ii revert partner mabtherarituxan case pointalready estab discontinuation phase iii lishe cancer medicineit test important area unmet medical need partner success rheumatoid arthritis rheumatoid arthritis autoimmune diseasesp pursue innovative strategic alliance com plement group strong internal research roche continue implement initiative roche pharma partnering unit continue help aim achieve well patient selection clinical build dynamic robust pharmaceutical development programme develop predic portfolio partner innovation p tive biomarker key area collabora roche pharmaceutical sign new tionbetween pharmaceutical diagnostic license agreementsinclude productrelate divisionstest enable prediction ofhow dif research technology partnershipsand ferent patient respond particular drug extend relationship longterm partner allow identification effective drug glaxosmithklineprotein design labs combinations patient subpopulation evotec limit undesirable effect acquisition glycart biotechnology com plete july represent significant addition business report foldout rd pipeline cid pharmaceutical therapeutic protein build strong portfolio biopharmaceutical promise candidate innovative therapy number disease area create proteinbased drug complex process pose challenge different manufacturing small mole cule roche pharmaceutical establish therapeutic protein initiative tpi build expand expertise area tpi global initiative unite contribution divisional function protein discovery development activity penzberg protein mulation basel cornerstone acquire recombinant protein especially monoclonal anti develop external internal knowledge body demonstrate value novel thera skill roche establish novel technology peutic agent high target specificity cellline development automate product isolation provide safe effective therapy advance analytical technology patient say stephan fischer global head biologic research development roche inception tpi help increase expertise competence function involve roche pharmaceutical rd productivity protein research development manufacturing number proteinbase project rise roche group unique position deliver key area e breakthrough medicine oncology inflammatory autoimmune disorder transplantation major development activity treatment adjuvant colon cancer advance renal cell carcinoma pancreatic prostate oncology ovarian cancerit test combina major clinical development programme tion tarceva nonsmall cell lung cancer explore benefit mabtherarituxanher nsclc ceptin avastin tarceva xeloda additional important indication roche evaluate mabtherarituxan chronic lymphocytic leukemia cll phase iii pro recent phase iii datum show avastin gramme explore use firstline treatment significant survival benefit metastatic nonsmall therapy ofrelapsing cll cell lung cancer metastatic breast cancer increase drug potential main phase iii iv trial herceptin ongoing stay cancer treatment set new standard metastatic adjuvant setting breast cancer treatment p regulatory filing cancer herceptin evaluate new indication plan addi treatment gastric cancer datum large tionavastin study phase iii trial clinical trial patient earlystage breast business report rd pipeline major development project successfully bring forward therapeutic area project d projectproduct generic pharmacological class indication phase partner cardiovascular r enzyme inhibitor type diabete ii metabolic disease r type diabete r enzyme modulator type diabete ii r type diabetes r type diabetes r dyslipidemia nippon shinyaku ns r cetp inhibitor dyslipidemia ii japan tobacco jtt r dyslipidemia r insulin sensitiser insulin sensitiser type diabete ii genitourinary disease r overactive bladder r gpcr agonist male erectile dysfunction ii hematology r cera continous erythropoietin receptor activator cancerrelated anemia ii nephrology r cera continous erythropoietin receptor activator renal anemia iii inflammatory autoimmune r mabtherarituxan rituximab anticd monoclonal antibody rheumatoid arthritis dmard inadequate responder iii genentech biogen idec bone disease r mabtherarituxan rituximab anticd monoclonal antibody rheumatoid arthritis antitnf inadequate responder file genentech biogen idec r valcyte valganciclovir inhibitor cmv replication ulcerative colitis r rheumatoid arthritis r kinase inhibitor rheumatoid arthritis ii r inflammatory bowel disease r actemra tocilizumab humanise antiil receptor monoclonal antibody rheumatoid arthritis iii chugai r actemra tocilizumab humanise antiil receptor monoclonal antibody systemic onset juvenile idiopathic arthritis iii chugai r humanise anticd monoclonal antibody rheumatoid arthritis ii genentech pro r osteoarthritis r autoimmune disease transplantation biocryst r cellcept mycophenolate mofetil impdh inhibitor lupus nephritis iii aspreva r cellcept mycophenolate mofetil impdh inhibitor myasthenia gravis iii aspreva neurological r alzheimer disease psychiatric disease r depression r schizophrenia r alzheimer disease r anxiety r schizophrenia oncology r mabtherarituxan rituximab anticd monoclonal antibody chronic lymphocytic leukemia relapse iii genentech biogen idec r mabtherarituxan rituximab anticd monoclonal antibody chronic lymphocytic leukemia st line iii r mabtherarituxan rituximab anticd monoclonal antibody indolent nonhodgkin lymphoma maintenance file genentech biogen idec r omnitarg pertuzumab antiher monoclonal antibody ovarian cancer ii genentech r omnitarg pertuzumab antiher monoclonal antibody metastatic breast cancer ii genentech r tarceva erlotinib egfr inhibitor glioblastoma multiforme ii genentech osi pharmaceutical r tarcevaavastin egfr inhibitor antivegf monoclonal antibody nsclc st line maintenance iii genentech osi pharmaceutical r erlotinib bevacizumab r tarceva erlotinib egfr inhibitor nsclc st line combo chemotherapy iii genentech osi pharmaceutical r tarcevaavastin egfr inhibitor antivegf monoclonal antibody nsclc nd line iii genentech osi pharmaceutical r erlotinib bevacizumab r tarceva erlotinib egfr inhibitor pancreatic cancer file genentech osi pharmaceutical r solid tumour r epothilone solid tumours ii kosan bioscience kos r solid tumour r solid tumour r monoclonal antibody metastatic breast cancer antisoma r humanise anticd monoclonal antibody hematologic malignancy genentech pro r epothilone solid tumour kosan bioscience kos r xeloda capecitabine fluoropyrimidine adjuvant breast cancer iii r xeloda capecitabine fluoropyrimidine adjuvant colon cancer combo iii r xeloda capecitabine fluoropyrimidine metastatic colorectal cancer st line combo iii r xeloda capecitabine fluoropyrimidine metastatic colorectal cancer nd line combo iii r avastin bevacizumab antivegf monoclonal antibody nsclc squamous ii genentech r avastin bevacizumab antivegf monoclonal antibody adjuvant colon cancer iii genentech r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer st line iii genentech r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer st line extension iii genentech r avastin bevacizumab antivegf monoclonal antibody metastatic colorectal cancer st line combo extension iii genentech r avastin bevacizumab antivegf monoclonal antibody renal cell carcinoma iii genentech r avastin bevacizumab antivegf monoclonal antibody nsclc st line iii genentech r avastin bevacizumab antivegf monoclonal antibody pancreatic cancer iii genentech r avastin bevacizumab antivegf monoclonal antibody ovarian cancer iii genentech r avastin bevacizumab antivegf monoclonal antibody prostate cancer iii genentech r solid tumour r herceptin trastuzumab antiher monoclonal antibody metastatic breast cancer combo hormonal therapy iii genentech r herceptin trastuzumab antiher monoclonal antibody adjuvant breast cancer iii genentech r herceptin trastuzumab antiher monoclonal antibody gastric cancer iii r bondronat ibandronic acid bisphosphonate metastatic bone pain iii respiratory disease r daclizumab anticd monoclonal antibody asthma ii pdl biopharma r dual integrin antagonist asthma ii r nuclear receptor agonist emphysema ii transplantation r daclizumab anticd monoclonal antibody transplant maintenance pdl biopharma viral r hiv infectious disease r antibiotic bacterial infection ii sankyo cs r hcv r hcv pharmasset r hcv maxygen r hcv pharmasset participation sg sigmart nicorandil acute heart failure file chugai epoch epogin epoetin beta chemotherapyinduce anemia iii chs recombinant parathyroid hormone osteoporosis ii daiichi asubio pharma ed activate vitamin derivate osteoporosis iii avs antevas nicaraven hydroxyl radical scavenger subarachnoid hemorrhage file cal humanise antipthrp monoclonal antibody bone metastases ii chc solid tumour cell therapeutic cgs femara letrozole aromatase inhibitor breast cancer file novartis gm mitemcinal fumarate motilin agonist gastroparesis irritable bowel syndrome ii val valine posthepatectomy ii participation raptiva efalizumab anticda antibody adult atopic dermatitis genentech lucentis ranibizumab antibody fragment vegf agerelate macular degeneration file novartis ophthalmic xolair omalizumab antiige antibody pediatric asthma peanut allergy ii iii novartis tanox optin opportunity pro vegf topical vegf diabetic foot ulcer genentech brfc baff inhibitor rheumatoid arthritis genentech r mabtherarituxan rituximab anticd monoclonal antibody primary progressive multiple sclerosis iii genentech biogen idec r mabtherarituxan rituximab anticd monoclonal antibody relapse remit multiple sclerosis ii genentech biogen idec r mabtherarituxan rituximab anticd monoclonal antibody lupus nephritis ii genentech biogen idec r mabtherarituxan rituximab anticd monoclonal antibody ancaassociate vasculitis iii genentech biogen idec r mabtherarituxan rituximab anticd monoclonal antibody systemic lupus erythematosus iii genentech biogen idec r avastin bevacizumab antivegf monoclonal antibody glioblastoma multiforme ii genentech r avastin bevacizumab antivegf monoclonal antibody adjuvant breast cancer ii genentech g topical hedgehog antagonist basal cell carcinoma genentech curis pro apoltrail cancer genentech r vascular target agent solid tumours ii antisoma dmxaa r ef modulator solid tumour arqule arq r glp glp type diabetes ii ipsen bim r calcineurin inhibitor renal transplant ii isotechnika isa r nonnucleoside reverse transcriptase inhibitor hiv medivir r alzheimer disease memory pharmaceutical end pharmaceutical division rd pipeline comprise project include phase transition preclinical clinical development new molecular entity nme additional indication fourteen nme currently phase phase initial study healthy volunteer possibly patient phase phase ii phase iii file regulatory review project enter phase ii efficacy tolerability dosefinde study patient phase development enter phase ii enter phase iii phase iiilargescale study patient statistical confirmation ofsafety efficacy bluetype signify indication blacktype additional indication therapeutic protein current december small moleculepharmaceutical partner innovation partner key element roche strategy develop innovative differentiate medicine patient pharma partnering pp com pany business development licensing department analyse external oppor tunitie year find cuttingedge science complement roche rd roche find external innovation focus emerge innovative science say immunologist marketing veteran hari kumar pps finder strategy team tell need drug condition effective treatment technology look pps alliance director deal approve contract negotiate finder specialist combine scientific exper prepare roche project integration ensure tise business acuman job identify communication partner open clear opportunity lead new treatment include new use exist roche product process roche rely core nere value flexibility respect partner culture finder identify opportunity large pp autonomy commitment side team assess base key question benefit collaboration organisationwide science viable differentiate opportunity partnering culture helps ensure continue access complement roche overall strategy com broad range external innovation expertise mercial potential senior management decision base answer cancer adjuvant setting show add extensive latestage programme study xeloda herceptin chemotherapy significantly reduce adjuvant breast cancer combination risk cancer recurrence population chemotherapy adjuvant colon cancer set eu filing indication plan secondline therapy metastatic quarter colorectal cancer continue recent interim analysis large collaborative group study tarcevaa human epidermal growth factor receptor drug firstline treatment advance pancreatic heregfr inhibitor design interfere cancer show add xeloda standard molecular signal play significant role chemotherapy gemcitabine significantly extend tumour cell growth numerous type ofcancer patient survival improve quality oflife currently test firstline adju vant nsclc setting combination headtohead phase iii study compare bon avastin secondline nsclctarceva dronat zoledronic acid treatment evaluate treatment glioblastoma multi metastatic bone pain commencedwith result formeone ofthe aggressive type ofprimary expect filing indication brain tumour plan europe business report pharmaceutical hematology nephrology anemia development actemra tocilizumab clinical development ofcerathe continuous mra ra progressing wellphase iii data erythropoietin receptor activator treatment japan present american college anemia progress track phase iii rheumatology meeting november renal programme product include trial treatment actemra significantly reduce involve patient chronic kidney progression joint damage improve ra disease dialysis dialysisthe sign symptomsbase datachugai phase iii trial dialysis patient plan file marketing application actemra successfully complete end ofcera ra japan half patient antianemia drug study long recruitment international phase iii trial pro dose interval week ceede plannedregulatory filing patient initial filingroche plan file mar eu expect chugai launch keting application worldwide cera renal actemra japan indicationcastleman anemia roche view patent diseasea rare condition cause severe enlarge infringement litigation initiate amgen ment ofthe lymph nod impediment development launch ofcera united states cellcept develop collaboration aspreva pharmaceuticals autoimmune applica rheumatoid arthritis autoimmune disease tion include treatment lupus nephritis rheumatoid arthritis ra autoimmune disor kidney complication associate autoim der characterise joint inflammation mune disease lupus erythematosus myasthe treatedcan result progressive joint destruc nia gravis chronic autoimmune disease charac tion andultimatelyloss offunctionits exact cause terised episode muscle weaknessphase iii unknownand curewithin clinical trial drug indication year develop raup patient waycellcept potential new treat xray evidence joint destructionand ment ofthese debilitate year unable work perform everyday fatal condition year january tasksra common autoimmune cellcept designate orphan drug disorder think affect mil treatment ofmyasthenia gravis fda lion people worldwidecurrent treatment include diseasemodifye antirheumatic drug dmard diabete biologic therapy antitnf drug roche complete twoyear animal car cinogenicity programme insulin sensitiser roche significantly advanced devel rrequire fda member opment oftwo medicine potential sub class agentsa final decision commence stantially improve treatment ofra ment phase iii clinical testing compound type diabete take fda mabtherarituxan selectively target agency complete review bcell therapy study diseasethe carcinogenicity datum eu filing august september product rheumatoid arthritis indication rep compound develop resent significant milestonethe filingsbase treatment type diabetes move phase ii data pivotal reflex trialcover use clinical testing glucokinase activator mabtherarituxan patient fail dipeptidyl peptidase dppiv inhibitor respond adequately current biologic therapy subgroup ra patient consider difficult treatpositive outcome see phase iib clinical trial dancer patient previously fail treatment dmard business report pharmaceutical set new standard cancer treatment st meeting american society clinical oncology asco orlando florida roche partner present datum unprecedented major phase iii trial successfully meet primary endpoint product generic indication clinical trial benefit avastin bevacizumab metastatic hernegative breast cancer improvement overall survival st line treatment e metastatic nonsmall cell lung cancer improvement overall survival st line treatment e metastatic colorectal cancer reduction risk death nd line treatment e herceptin trastuzumab herpositive breast cancer adjuvant treatment reduction risk disease recurrence nsabp b ncctg n joint analysis herpositive breast cancer reduction risk disease recurrence adjuvant treatment hera mabtherarituxan relapse indolent nhl improvement response rituximab maintenance treatment gslg duration year tarceva erlotinib pancreatic cancer st line treatment pa improvement overall survival expand biotech production capacity oceanside california facility acquire genentech biogen idec june currently roche group continue reconfigure convert produce avastinmanufacture manufacturing capacity meet require ofbulk drug substance expect commence ment ofa change product portfolio increase fda licensure expect half efficiency global manufacturing opera ofin genentech receive fda licensure tionsin particulara shift chemically derive new avastin manufacturing facility porrio active pharmaceutical ingredient biolog spain ics corresponding trend sterile liquid dosage form drive current activity work new basel switzerland penzberg area technical development activity reflect production facility therapeutic antibody impact pharmaceutical division schedule technical completion dynamic rd portfolio include development ismove ahead plan inlicense product roche ongoing pro ject reduce supply chain complexity andoptimise inventory level remain track access medicine major new facility dedicate year primary role roche pharmaceu new biotech production facility epoetin tical division discover develop com cera penzberg germany stateoftheart mercialise innovative medicine adoption packaging storage facility injectable drug policy extend access critically need mannheim germany plant high product people affect poverty potency pharmaceutical product shanghaithe world integral ofhealthcare mission new penzberg mannheim facility addition support local initia operational middle ofthe shanghai tive expand healthcare accessroche imple facilitythe ofit kind chinais schedule mented patent pricing policy join come stream yearit produce cellcept major international effort aim address xeloda chinese market problem business report pharmaceutical roche file new patent medicine step take include implement tiere pricing develop country define system significant reduction pandemic unnor enforce patent hold use licensing agreement local company country response devastating production drug pandemic use hivaids pandemic company extend india china addition take unprece policy subsaharan africathe poorest dent step ramp tamiflu production capac hardesthit region ity meet world demand tamiflu p roche work national institute price roche charge product low allergy infectious disease international lowermiddle income country virology expert expand information base correspond price switzerland launch optimal use tamiflu roche supply hiv medicine invirase hn avian influenza strain viracept profit develop country subsaharan africaas resultreduce price access medicine issue affect product apply ofall people live develop world pose significant hivaid worldwide challenge industrialise countriesas wellin united statesfor exampleroche commit additionroche member ofthe accelerate make sure patient need roche access initiativewhich helping increase num drug access itwhether patient senior ber ofhivaid patient develop country citizen treat canceror member receive treatment company support work family face organ transplant hiv treatment access programme roche patient assistance program establish care programme african country industry provide cambodian treatment access programme prescription drug free charge qualifying addition provide fundingmedicine diag patient need lack prescription nostic programmesroche coverage mean pay contribute provide training hivaid care treatment hundred healthcare pro roche found member partner fessional african country ship prescription assistance programme cambodia ensure access healthcare sponsor pharmaceutical research worldwidepand visit wwwrochehivcom manufacturers america represent countrys lead pharmaceutical research recent extend access vital biotechnology companiesthe programme offer hivaids treatment world needy area single point ofaccess public private roche announce january thatas patient assistance programme new technology transfer initiativethe company provide local manufacturer sub similarly genentech provide market prod saharan africa develop country uct free charge eligible uninsured patient technical expertise require produce generic treat united states genentech hiv medicinesthis assistance offer free access care foundation genentech condition attach endowment cystic fibrosisgenentech member partnership prescription assis threat avian flu pandemic represent tanceto support patient access therapie critical global health challengeand roche disease genentech donate closely involved ensure vital medicine approximately million dollar independent available neededfollow party public charity offer copayment ing warning global assistance eligible patient influenza pandemic imminent roche ensure worldwide availability influenza drug tamiflu pandemic use business report diagnostic division brief sale million chf operating profit exceptional item million chf include charge equity compensation plans number employee key figure change change millions chf chf local currency sale sale diabetes care centralize diagnostic molecular diagnostic near patient testing apply science ebitda operate profit research development exceptional item diagnostic executive team january severin schwan ceo division roche diagnostic silvia ayyoubi human resource heiner dreismann molecular diagnostic christian hebich finance service tiffany olson north america volker pfahlert centralize diagnostic apply science burkhard piper diabetes care jrgen schwiezer emea europe middle east africa robert yates business development business report diagnostic result sale region roche diagnostic maintain leadership posi tion difficult market divisional sale rise local currency swiss francs europemiddle east africa dollar broadly line global market japan growth asiapacific worldwideroche diagnostic launch iberia new product include complete new latin america generation product replace old flagship north america offering divisions key diabetes management portfolio year division italic growth rate expand new highpotential market segmentssuch dna sequence operating profit exceptional item decrease local currency billion swiss franc business area result margin decline percentage point primarily heavy diabetes care price pressure market startup cost new manufacturing facility new product roche diabetes carethe market leader diabete andhigher depreciation chargesthe high depre management post sale growth local ciation result increase instrument currency placement business unit launch number ofinnovative product second halfofthese include accuchek compact plus glucose monitoring system builtin test strip drum lancing device accuchek aviva successor accuchek advantage monitor new market accuchek spirita menu drive insulin pump set new standard flexibility reliability addition business unit introduce accuchek pocket compass late software mobile diabetes selfman agement feature bolus calculator module enable user calculate bolus insulin requirement basis ofcurrent blood glucose estimate food intake personal param business report diagnostic selling product line sale change product line market segment business area millions chf local currency accuchek diabete management diabetes care cobas integra clinical chemistry centralize diagnostic roche hitachi elecsys immunodiagnostic centralize diagnostic amplicor test clinical molecular molecular diagnostic cobas amplicor diagnostic cobas ampliscreen nucleic acidbase molecular diagnostic blood screen coaguchek coagulation monitoring near patient testing exclude hia homogeneous immunoassay eterswith new generation ofproductsroche term goalplacement ofelecsys e system diagnostic continues lead way key advanced yearreache record area effective diabetes management glucose highand thank strong demand elecsys monitoringinsulin delivery datum management probnp assay roche lead supplier laboratory test cardiac marker sale grow body evidence document elecsy assay help benefit regular blood glucose monitor scientific paper publish ntprobnp timea multicentre study verify inclusion marker patient glucose selfmonitoring reduce morbidity management guidelinessee patient story p mortality people type diabete finding like expect motivate people global trend mount pressure health type diabetes monitor glucose care budgetscombine shortage train closely laboratory staffmean laboratory increas ingly dependent automatedintegrate labora food drug administration fda tory system offer costefficiency high complete inspection roche diagnostic performancethis create ideal market environ facility burgdorf switzerland final deci ment rollout cobas new sion lift import alert generation modular analyser mediumsize pump facility pende laboratory centralize diagnostic investment new technology automate task precede follow actual testing roche centralized diagnostic supply integrate laboratory beginning pay total solution clinical laboratory busi expand cooperation agreement sign ness area report sale growth local curren german company pvt probenverteiltechnik ciestake lead time impor cover preanalytical automation tant segment ofthe diagnostic market strengthen position aleade provider total laboratory solution rsda new sys growth primarily continue success tem provide complete preanalytical automation immunodiagnostic portfolio roche successfully launch pursue leadership immunodiagnostic market move step close achieve medium business report diagnostic new marker point way well care immunodiagnostic represent major share global vitro diagnostic market onefourth count climb roche tap potential innovative immunodiagnostic marker address unmet medical need immunodiagnostic exploit basic feature bodys natural defence system disease viruse bacteria foreign substance collectively refer antigen enter body respond produce antibody bind antigen neu tralise response highly specific datum ongoing study assay gross key normally fit lock antibody react hadern university hospital munich germany antigens stimulate production encouraging follow breast cancer surgery blood test determine baseline level immunodiagnostic test mimic natural defensive tumour marker test marker reaction explain joachim eberle head research repeat sixweek interval rise development roche centralized diagnostic level indicate growth new cancer cell specificity antibodie month patient develop detect presence particular antigen body symptom enable physician action soon help diagnose disease save precious time natural mechanism antibodyantigen interaction give new hope immunoassay example identify patient health professional tumour marker protein breast cancer patient early molecular diagnostic company test hivhcv hepati tis b hbv approve eu sale growth market share authority screen livingdonor cadav roche molecular diagnostic remain eric organ tissue blood plasma clear leader increasingly competitive tissue cadaveric source include skin market environment blood screening bone ligament roughly mil virology main growth lion medical procedure year transmit driver viral infection blood tissue single donor transplant average year roche diagnostic enter insome case recipientsthis blood screen marketover million blood highlight significance approval donation screen roche hiv end year regulatory filing hepatitis c hcv test roche submit europe nextgeneration cobas global leader sector volume blood screen systemwhich expect unit testedand reach market business report diagnostic core virology portfolio strengthen near patient testing integrate cobas ampliprepcobas taqman system offer laboratory new roche near patient testing report increase capability fully automate sample preparation fullyear saleswith positive growth dnarna analysis addition viral core segmentscardiologycoagulation monitoring load test use platform approve blood gaselectrolytesit leader decen marketing europe test measure tralise testing testing outside hospital labora amount ofhivhcv hbv human plasma tory patient selfmonitore viral load key indicator assess disease progression treatment response drug resis sale coagulation monitoring product rose tance regulatory filing test especially strong growth record plan theunite statesa recent clinical trial show patient selfmonitore coaguchek roche diagnostic lineararray hpv genotyping system reduce risk severe complication test receive ce mark approval june minor hemorrhage patient commercially available test capable oral anticoagulant therapy reduce identify high lowrisk genetic variant mortality heart valve replacement human papillomavirus hpv result support costeffectiveness majority hpv infection clear spontaneously patient selfmonitoring evidence persistent infection highrisk hpv genotype modern diagnostic help reduce recognise significant risk factor develop cost ofhealthcaresee patient story p ment cervical cancer new roche test expect contribute significantly early market launch ofthe cardiac ntprobnp test identification ofwoman risk cervical cancer outlicensing agreement marker not probnp expect boost sale cardiol july roche open world large ogy sectorcardiac ntprobnp doctor manufacture facility pcrbase product office intensive care unit rule heart new jersey usa pcr polymerase chain reac failure monitor heart failure patient tion technique produce million copy virtually dna sequence short placement roche diagnostic blood gas time aid detect infectious agent electrolyte analyser double compare genetic variation quickly reliably year year roche molecular diagnostic increase kit output new connectivity remote testing device facility line able continue critical element ofpointofcare testing hospital meet steadily grow demand prod setting roche cobas datum management uct softwarelaunche technological mile stone worldwide commercial success amplichip cyp test dna software connect roche nonroche microarraybase test clinical diagnostic pointofcare device hospital hospital use receive regulatory clearance january network follow approval launch europe major laboratory unite applied science state add test s vice offering test help guide physician roche apply science maintain position select medicine dosage suitable fiercely competitive marketplace sale rise patient mark major step year business area supply hightech personalise healthcare patient story system reagent research laboratory p spur new product launch sale gather considerable momentum course business report diagnostic diagnostic help squeeze healthcare budget diagnostic help healthcare system use precious resource efficiently fact addition medical benefit diagnostic test create economic value diagnostic test provide basis twothird medical decision account healthcare expenditure year new technology regard cost driver look ing treatment process clear innovative diagnostic help healthcare deliv treatment start cuttingedge roche ery costeffective provide sounder diagnostic enable physician monitor patient basis medical decisionmake help response physician tailor treatment closely theindivid ual need patient modern test forexample roche diagnostic lead way researching easy determine good medicine develop innovative diagnostic test dosage particular patient result patient change way medicine practice receive well treatment apt suffer commit promote well understand costly adverse event value diagnostic information stake holder virology provide excellent example eco nomic benefit diagnostic product early diagnosis roche diagnostic proactively pursue effective treatment hepatitis prevent com research document medical plication liver failure liver cancer diag economic value diagnostic information say nostic instrument test kit roche geoffrey crouse head market development possible detect virus early governmental affair context key question roche test establish viral geno maximise health type treatment novel medicine like money spend pegasys tailor infect viral strain yearwith business area report doubledigit form mark roche entry attrac increase fourth quarter tive sequence research market employing awardwinne nanotechnologybase approach genome sequencer lightcycler sequence system product roche apply sciences important emerge strategic alliance form new offering genome sequencer roche technologys usbased system enable researcher sequence long dna inventor life science roche hold exclusive fragment entire genome time sale marketing right life science fast commercially available plat sequence system life science market business report diagnostic major product launch business area product diabete care accuchek aviva highend successor advantagesensor blood glucose monitoring system accuchek pocket compass nextgeneration diabete management software accuchek integra blood glucose monitoring system fully automate test strip handle accuchek compact plus blood glucose monitoring system integrate strip drum lance device onehand operation accuchek flexlink infusion set centralized diagnostic cobas integra analyser closedtube sample dedicated hbac glycate hemoglobin analyser basis cobas integra improve reagent prostatespecific antigen myoglobin troponin prolactin forelecsys platform molecular diagnostic integrate cobas ampliprepcobas taqman instrument hcv hiv hbv fully automate pcr system assay quantitative detection hiv hepatitis c b cobas ampliprepcobas amplicor hcv qual v qualitative detection hepatitis c virus ivd cobas ampliprepcobas amplicor hiv monitor test monitor hiv viral load usivd cobas ampliscreen hcv hbv hiv test screen organ tissue donation usivd new indication cobas ampliscreen hbv test detect hepatitis b virus human plasma usivd linear array hcv genotype test determine hepatitis c genotype ce ivd linear array hpv genotype test identifie genotype human papillomavirus ceivd cobas taqman ct test chlamydiace ivd amplichip cyp test microarray drug metabolism test ivd lightcycler factor ii v tests factor ii v leiden clotting disorder ce ivd near patient testing cardiac ntprobnp rapid accurate assay quantitative determination ofntprobnp diagnosis management heart failure patient coaguchek xs handheld system coagulation selfmonitore omni version software update omni blood gaselectrolyte system cobas new webbase datum management solution pointofcare testing inhospital apply science universal probelibrary set innovative probebase detection system quantitative pcrtest genome seqencer complete platform highthroughput sequence lightcycl novel platform gene expression mutation analysis lightcycler ivd version lightcycler dna amplification system ce ivd ivd clinical use ce european ce mark certification conformit europenne business report diagnostic lightcycler realtime pcr system chipsa protein chip system impact currently novel platform gene expression mutation undergo feasibility study analysis combine speed exceptional accu initially accelerate clinical testing new racythe new system support current probe marker mat application molecular diagnostic research development research activity roche molecular diagnostic focus advance pcr relate research development expenditure total technology enable development new gene nearly million swiss franc approximately base tests taqman amplichip plat salessignificantly division form roche work new approach competitor spend molecular diagnostic increase total throughput pcrbase immunodiagnostic diabetes care business analyse test multiple viral human account large share ofexpenditure genetic marker simultaneously run diabetes care september roche mayo clinic minnesota usa sign agreement collabo research development effort business rate develop itenable drug dose unit aim make diabetes management selection system use treat psychiatric simple example develop software patient information provide system gear special need offrequent testerswho base patient test datum obtain cope huge amount ofdata amplichip cyp testmayo clinic explore use system wide range psy additionroche work minimally inva chotropic drugsthis area clinical practice sive glucose measure technology require drug try minute blood sample sample long treatment cycle time order find continuous blood glucose monitoring system good particular patient ultimate aim create artificial pancrea system capable mimic natural pattern molecular diagnostic steadily gain ofinsulin release healthy individual importance oncologyroche effort area aim primarily develop test early centralize diagnostic cancer detection risk stratificationparticularly solid tumour cancer breast roche centralized diagnostic develop total labo prostate colon leukemia candidate ratory automation system increase laboratory marker identify currently productivity reduce cost reliable diag evaluate potential use important nostic test contribute well patient care application key area ofinter include cardiovascular disease cancer rheumatoid arthritis largescale international clinical research pro gramme investigate leukemia classification additionroche step research way complete new biomarker ofhigh diagnostic value monitor different subtype leukemia ing disease progression evaluate treatment respond treatment responsebiomarker singly incom choose effective available medication bination source informationparticularly type oftherapy right outset particu complex disease like cancer test multiple lar leukemia subtype particularly important marker mean obtain acute leukemia progress rapidly conclusive result generation system programme compare result obtain measure marker combination protein amplichip leukemia test different laboratory business report diagnostic key product launch schedule business area product diabetes care accuchek successor accuchek meter offering improve feature set anddesign centralize diagnostic cobas series consolidate clinical chemistry immunochemistry testing medium highworkload laboratory modular expandable reconfigurable site configuration cobas c cobas e modules cobas series consolidate clinical chemistry immunochemistry test small mediumworkload laboratory link cobas c cobas e psm datum manager cobas c clinical chemistry electrolyte analyser extrasmallworkload laboratory standalone system cobas solution laboratory information system support step laboratory testing order entry result report feature connectivity sample management quality control validation capability cobas solution central lab datum management system wammiddleware instrument interface consolidation provide resultrelate reagent test information molecular diagnostic lightcycler septifast test ce ivd world diagnostic assay detection sepsis cause pathogen directly blood cobas mpv ce ivd multiplex detection test hiv hcv hbv cobas blood screening system cobas taqman hcv v test monitor hcv viral load apply science genome sequencer system nextgeneration system capability sequence large genome lightcycl include new software module extension lc allowinguse broad range application interlaboratory robustness intend near patient testing confirm datum roche gene discovery pro jects prototype test expect ready mediumterm goal roche near patient research application end testing develop mobile device form urgent medical test matter microarraybased product currently minute development amplichip p test research collaboration investigate potential business area plan complete line clinical application test schedule new instrument market p gene ofa family ofgene call begin refresh product portfolio tumour suppressors code protein pilot launch coaguchek xs coagulation prevent damage cell reproduce muta monitorthis userfriendly nextgeneration device tion p gene find virtually builtin quality control system capable tumour typesby identify mutation affect detect virtually potential source error p function activitythe amplichip p test testingthus make anticoagulant therapy day help physician select anticancer safe medicine well suit patientsneed business report diagnostic apply science roche apply science focus develop high quality system reagent use life science research particularly highpotential area proteomic dna sequence analysis example business area work broaden research use ofthe newhighly versa tile lightcycler instrument innovative geno type product software upgrade introduce product expand application ofthe genome sequencer reach market work way system fast access diagnostic amplicare programme way roche diagnostic helping improve healthcare delivery hivaids patient part ofthe world need great subsaharan africa country designate united nation develop inception programme supply hiv viral load test sharply reduce price test story sustainability continuity care criticalwe contribut ing front provide expand training continue education opportunity doctor nurse support effort monitor health outcomeswe strive match effort local needsworke closely laboratory hospital example determine service type oftechnical assis tance feasible suitable develop target solution roche diagnostic plan expand amplicare programme additional countrieswith focus reach country list un lowincome economy preparatory talk initiate purpose eastern europe latin america additional country asia business report medication help osteoporosis month business report grow old not mean go slow senior sale account manager ginger la motta branchburg new jersey dote grandchild enjoy ride shoulder diagnosis osteo porosis year ago realise simple pleasure like risk health osteoporosis bone condition common postmenopausal woman people tend think bone hard unchanging fact dynamic living tissue constantly break rebuiltafter menopause rebuild slow bone mass decrease make bone weak likely break ginger eat healthy diet exercise regularlyto osteoporosis control take onceamonth boniva oncemonthly oral bisphosphonate oral bisphosphonate take morning stomach patient stay upright eat halfhour hour busy schedule onceamonth boniva ideal solution ginger reduce risk fracture take tablet monthand s relaxed play grand child prevention reduce consequence disease help patient maintain quality life boniva ibandronic acid maintain actually build bone density reduce risk fracture course patient need stay therapy benefit monthly boniva s lot easy patient tablet year business report board director executive committee corporate governance board director corporate executive committee board director economist international mon etary fund world bank washingtondc annual general meeting february john bell andr hoffmann franz b board proposal adoptedchairman humer elect additional fouryear term board franz bhumer continue board ofdirector director serve executive capacity rocheand majority seat board current board term rolf hnggi peter hold independent director brabeckletmathe deanne julius horst teltschik end annual general meetingon february meeting corporate executive committee board intend nominate mr brabeckletmathe ms julius mr teltschik reelection heino von prondzynski ceo division roche director term offour year diagnosticsha decide leave roche year pursue personal interest join roche rolf hnggiwho serve vicechairman march contribute significantly board decline stand diagnostic division achievementsprovide electionmr hnggi increasingly active leadership help division expand private investor pharmaceutical startup global market leadership successfullythe board companiesa situation potentially director like additional rise conflict interest opportunity thank mr prondzynski valu roche decision help ensure con able contribution wish good tinue independence capacity future board ofdirector corporate executive com mittee extend sincere thank mr hnggi severin schwan join corporate executive forhis year ofdedicate service group committee new ceo division roche diag nostics january schwan yearold addition aforementione nominee austrian doctorate law degree reelectionthe board recommend economic begin career roche election beatrice weder di mauro roche thecorporate finance department baselfollow high governing body yearold native ing international assignmentshe serve baselm weder di maurohas professor head ofglobal finance service diagnos economics university mainz germany tic division charge serve germanys council division regional operation asiapacific economic expert august prior business report board director corporate executive committee board director january leftjohn bell rolf hnggi peter brabeckletmathe brunogehrig andrhoffmann franz b humer lodewijk jr de vink deanne julius walter frey andreasoeri horst teltschik year birth term endsfirst elect board director dr franz b humer f chairman prof bruno gehrig c e vicechairman independent lead director rolf hnggi b e vicechairman prof john irving bell c e peter brabeckletmathe e lodewijk jr de vink e walter frey b e andr hoffmann c e dr deanne julius b e dr andreas oeri b e prof horst teltschik e secretary board directors dr gottlieb keller honorary chairman board directors dr fritz gerber finance investment committee presidium board directorsnomination committee b audit corporate governance committee e nonexecutive director c remuneration committee f executive director committee chairperson step february january business report board director corporate executive committee burkhard gpiper name enlarge effective january eduard holdener peter corporate executive committee appointment hug rolf schlpfer osamu nagayama effective january appoint member roche enlarge yearold german hold degree business corporate executive committeeall man administration join boehringermannheim assist executive management permanent group later acquire roche hold participant committee january management position marketing appoint general manager roche diag nostics canada head roche centralize diagnostic mr piper head roche diabetes care end mr pipers predecessor staffan ek retired end year board director thank mrek significant role strengthen roche diabete care business contribution success ofthe group business report board director corporate executive committee corporate executive committee december leftjonathan kc knowle pierre jaccoud heino von prondzynski staffan ek william burns eduard holdener franz b humer peterhug erichhunziker rolf schlpfer gottlieb keller osamu nagayama year birth position corporate executive committee dr franz b humer ceo roche group dr erich hunziker chief financial officer deputy head corporate executive committee william burns ceo division roche pharmaceutical heino von prondzynski ceo division roche diagnostic prof jonathan kc knowles head global research dr gottlieb keller head corporate service human resource enlarge corporate dr eduard holdener head global pharma development executive committee dr peter hug head pharma partnering staffan ek head business area diabete care rolf schlpfer head corporate communication osamu nagayama president ceo chugai secretary pierre jaccoud head chairmans office corporate executive committee statutory auditor kpmg klynveld peat marwick goerdeler sa roche holding ltd principal auditor john morris group auditor compliance officer dr andreas greuter direct dial number january dr severin schwan january burkhard g piper end business report corporate governance corporate governance roche group meet requirement finance investment committee respect corporate governance comply chairmanrolfhnggi exist legal regulationsthe swx swiss remuneration committee stock exchange directive include com chairmanbruno gehrig mentarie swiss code good practice corporate governance promulgate swiss committee presidium business federation economiesuisse exist chair independent director internal company regulation particular company article incorporation bylaw bylaw board director contain consider principle govern manage detail internal structure board ment supervision company include allocation authority responsibilitie necessary check balance order mandate board committee infor ensure good corporate governance mation control mechanism available board dealing corporate management combine print annual report key publish internet link roche website wwwrochecom enable reader gain snapshot article ofthe bylaw ofthe reporting date uptodate overview board ofdirectorsthe independent lead director company key corporate governance information decision request annual report contain information member convene board meeting available december ofthe give yearwhile attendance chairman roche board internet provide source permanent meet year assess chairman perfor constantly update information company mancethis meetingwhich hold absence article incorporationthe bylaw cur chairman chair independent ricula vitae member board direc lead director tor executive committee regularly update available internet board ofdirector periodically conduct self require information assessment ofit performancein selfassess ment focus number area include organisational structure board cooperation board executive director committeewa conduct assistance ofa specialist consulting firm roche board director organise ensure group business conduct remuneration responsibly focus longterm value creation board director remuneration member board roche holding ltd delegate certain responsi ofdirector bilitie committeesas january members board director committee receive remuneration show table remuneration member board presidium ofthe board ofdirector directorsfor serve board nomination committee chairmanfranz bhumer httpwwwrochecomhomecompanycomgovhtm audit corporate governance committee httpwwwrochecomhomecompanycomgov chairmandeanne julius comgovbylawshtm business report corporate governance remuneration member board director additional compensation remuneration committee member chf chf fb humer b gehrig r hnggi j bell p brabeckletmathe ljr de vink w frey ahoffmann da julius oeri h teltschik total committee membershipyear exclude member presidium vicechairman chf remuneration pay chairman board fb humer executive member board director isdeducte agree salary remuneration member corporate executive committee remuneration serve independent lead director vicechairman board remuneration serve vicechairman board remuneration additional compensation pay remuneration member corporate nonexecutive member board direc executive committee tor serve aforementioned capacity remuneration committee decides total swiss franc previous remuneration member corporate year swiss francs executive committee cash paymentsbonusstock option ssar approve principle nonexecutive member board pension fund benefit board director director award sharesnonvote proposal remuneration committee equity security nesstocksettle stock appre decide performance share plan psp ciation right ssar stock option december hold unvested compensation component ssar option award previous year psp plan intend align compensation longterm success ofthe company connection acquisition glycart july finance report note member corporate executive roche group consolidated financial committee receive salary bonuse stock statement change group organisation optionsstocksettle stock appreciation right relate party group pay ssar nonvoting equity securities rolf hnggi swiss franc considera show follow table tion shareholde glycartthis equiva lend pershare basis amount pay member corporate executive committee shareholder glycart stock additionally receive annual expense allowance swiss franc chief executive officer otherwiseno additional remuneration pay receive annual expense allowance member ofthe board ofdirector swiss francsin member ofthe corporate executive committee total receive expense allowance total swiss franc refer stock optionsstocksettle stock appreciation right ssar business report corporate governance remuneration member corporate executive committee cash payment chf annual salary annual salary annual salary bonus bonus bonus fb humer wm burn e hunziker ga keller jkc knowle h von prondzynski total b stock optionsstocksettle stock appreciation right ssar ssar stock option stock option value chf value chf value chf fb humer wm burn e hunziker ga keller jkc knowle h von prondzynski total refer stock optionsstocksettle stock appreciation right ssar blackschole valuation describe section stock optionsstocksettle stock appreciation right ssar page richard tlaube step corporate year programme effect executive committee december performance evaluate basis ofmarket leave company june richard price dividend yield ie total shareholder tlaube receive continue salarybonus sev returntsr order reduce effect erance payment totalling million swiss franc shortterm market price fluctuation tsr base average market value c performance share plan psp month october december members corporate executive commit begin ofthe programme compare aver tee member ofsenior management age ofthe month october decem performance major impact roche ability ber ifan investment roche security achieve corporate objective indi equal outperform peer set vidual worldwide participate new psp pro roche tsr increase gramme establish duration programmethe board ofdirector begin threeyear period elect increase number ne award theprovision ofthis programme replace maximum twofold event psp programme number ofne investment roche security underperform reserve participantsthe actual distribution security depend peer set abbott laboratories altana amgen astrazeneca extent investment roche security share bayer becton dickinson biogen idec bristolmyers nes outperform average return invest squibb eli lilly glaxosmithkline johnson johnson ment securities issue peer setof com merck novartis pfizer serono sanofiaventis schering panie operate industry ag scheringplough takeda wyeth business report corporate governance performance share plan psp number number ne ne originally target targeted psp psp psp value assumption value psp number number value chf value chf fb humer wm burn e hunziker ga keller jkc knowle h von prondzynski total value assumption evaluate yearend price december chf genussschein ne base number ne originally target subject change allocation value number ne originally target plan december spread relevant period time ie year board director vote actual allocation ne originally target december accord tsr growth achieve value year psp double number ne originally target accord market value growth achieve spread relevant year total period effective time plan average return deliver peer company reserve member corporate executive few ne award committee show table abovethe board provision programme ne ofdirector decide actual distribution roche performance rochetsr peer group average tsrperformance total shareholder return tsr value chf invest roche market capitalisation billion chf roche security chf nonvoting equity security ne share price translate constant chf exchange rate tsr stock price plus dividend business report corporate governance ne cash equivalent plan close indirect benefit ofthe reporting year employer contribution social security scheme pension plan year roche security share groupwide employee stock purchase plan roche ne include dividend yield outper connect respect member corporate form average return deliver peer executive committee show table pharmaceutical diagnostic company indirect benefit roche rank second end psp pro roche connecta voluntary stock purchase gramme time market planemployee opportunity buy roche value roche increase billion swiss nonvoting equity security nes francs billion swiss franc equivalent equal annual salary growth billion swiss francsthe dis discountne purchase plan tribution dividend total billion swiss subject hold periodwhich switzerland franc year current psp programme e remuneration emolument loan base move threemonth average corporate officer constant exchange rate roche year gottlieb keller take mortgage loan rank number compare peer set swiss franc pension fund company operate industry fhoffmannla roche ltd interest rate pa interest rate loan fix roche market value increase billion december swiss franc billion swiss francsequivalent growth billion pension obligation seven member swiss franc distribution corporate executive committee widow dividend total billion swiss transfer pension fund franc onetime payment swiss franc fund cover result addi average total shareholder return tsr tionalliabilitiespension total swiss ofthe peer set constant exchange rate sig francswere pay totwo corporate executive nificantly low tsr roche committee member security point high average tsr peer company constant additional remuneration pay exchange rate current member ofthe corporate execu tive committee indirect benefit pension fundsmgb ahvivalv roche connect chf chf chf fb humer wm burn e hunziker ga keller jkc knowle h von prondzynski total mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit ahvivalv swiss social security programme provide retirement disability unemployment benefit business report corporate governance f high total remuneration stock optionsstocksettle stock appreciation chairman board director ceo right ssar franz bhumer member ofthe board member ofthe corporate executive committee december members corpo high total remuneration rate executive committee hold optionsssar refer remuneration ofthe member ofthe cor january show table porate executive committee subject change page allocation computation relate threeyear performanceshare plan psp salary follow high total remuneration chf cash payment stock optionsssar value base blackschole formulaminus performance share plan pension fundsmgb roche connect total value blackschole valuation describe section stock optionsstocksettle stock appreciation right ssar refer remuneration member corporate executive committee c performance share plan psp pay mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit payment pension scheme shareholding option show table issue roche employee stock option option director andr hoffmann andreas oeri entitle holder purchase roche non member founder family vote equity security nesgenussschein closely associate belong share holder group pool voting rightsat end term establish option group hold share planthe strike price option show issue share andr hoffmann serve closing price roche ne trading day spokesman shareholder group detail prior roche annual media conferenceall information group find option show nontradableonethird finance report note roche group option subject vest period consolidated financial statement relate par yearonethird vest period year tie note financial onethird vest period year statement roche holding ltd unvested option lapse compensation addition december nonexecu member voluntarily leave company tive member ofthe board ofdirector person vest option exercise limited closely associate held share period oftimeifthey tradablethe fair value member corporate executive commit option calculate date tee person closely associate hold issue base blackschole formula share date deduct average twoyear vest period business report corporate governance stock optionsssar number stock optionsssar hold december members executive committee total number strike price chf expiry date allotment value stock option ssar chf value base blackschole formula minus ssar ssar show table issue relationship group auditor statutory roche january basis ofthe roche auditor longtermprogram instead stock option ssar right benefit financially annual general meeting roche hold increase value nonvoting equity security ltd february kpmg klynveld peat nesgenussschein grant date marwick goerdeler sa kpmg elect exercise datethe strike price ssar group auditors statutory auditor informa term perennial plan close tion appointment ofthe group auditor price roche ne trading day date principal auditor take roche annual media conference office provide group auditor anniversary ofthe grant dateall remain ssar statutory auditor participate audit shall vestedonethird ofthe ssar subject corporate governance committee meeting vest period year onethird auditor write oral report vest period oftwo yearsand onethird vest result audits audit corporate period yearsvested ssar exer governance committee oversee assess cise seven year grant date ie auditor make recommendation board exchange ofssar gain ne unexercised information responsibility ssar lapse compensation audit corporate governance committee tradablethe fair value ofthe ssar cal article bylaw group auditor culate date issue base black statutory auditor participate meet schole formula deduct ing audit corporate governance average twoyear vest period committee strike priceexpiry date allotment price report ofthe group statutory auditor show tablethe value option set forth page respectively ssar table remuneration ofmember finance report ofthis annual report corporate executive committee b stock optionsstocksettle stock appreciation right kpmg receive follow remuneration ssarson base calculation service group auditor statutory method time ofissue auditor roche holding ltd roche financial company httpwwwrochecomhomecompanycomgov comgovbylawshtm business report corporate governance millions chf capital structure auditing service information roche capital structure auditrelated service provide finance report note tax consultancy service financial statement roche holding ltd total additional detail contain article ofincorporation ofroche hold ltd group auditor statutory auditor change equity detailed finance elect year annual general meeting report note financial statement ernst young ltd receive follow remuner roche holding ltd ation services auditor ofgenentech company share capital chugai swiss franc divide fully pay bearer share nominal value swiss franc millions chf eachthere limitation transfer genentech chugai audits share cap voting right consulting service provide depositshare vote restric genentech chugai tion total authorise conditional capital addition nonvoting equity secu additional information relate corporate ritie ne issue bearer formthey governance form ofthe share capital confer vote rightseach ne confer right group structure shareholder share participate available earning roche operate business organise liquidation proceed follow repayment divisionspharmaceutical diagnostic share capitalroche ne right pharmaceutical division comprise taine thereto inclthe provision secure business segment roche pharmaceutical claim describe article genentech chugai incorporation ofroche hold ltd diagnostic division consist offive business information debt instrument area diabete care near patient testing cen issue outstanding bond provide tralize diagnostic molecular diagnostic finance report note roche apply sciencebusiness activity carry group consolidated financial statement debt group subsidiary associate com panie significant subsidiary associate additional information employee stock company list finance reportnote option provide finance reportnote roche group consolidate financial roche group consolidate financial state statement subsidiary associate compa ment employee stock option equity niespage compensation benefit major shareholder list finance roche issue option apart reportnote roche group con award employee issue solidated financial statement equity attribut connection debt instrument able roche shareholder relate party option award employee page note financial debt instrument issue statement ofroche hold ltd effect roche share capital andr hoffmann andreas oeri serve board ofdirector representative ofthe share holder pool voting right receive remuneration mention remuneration member board director relationship exist shareholder httpwwwrochecomhomecompanycomgov pool voting right comgovartihtm crossshareholding business report corporate governance board director corporate executive finance investment committeethree committee meeting information member board remuneration committeetwo meeting director include year management contract fall elect year term end mean ofsubsection ofthe swx corporate executive committee list directive information relate corporate page curriculum vitae infor governance mation board executive committee member include information board mem participatory right shareholder bership available internet participatory right shareholder ofthe nonexecutive member ofthe board define roche article ofincorporationas ofdirector member ofthe corporate roche share issue bearer executive committee roche restriction admission annual general group subsidiary financial meetingswith exception share year precede current reporting period deposit specify period date internal organisation board direc meeting admittance card tor division ofauthority responsibil issued shareholder provide itie board management article incorporation share govern bylaw holder elect represent board director establish system shareholder annual general meeting control oversee audit article incorporation contain restriction corporate governance committee consist exercise ofvote rightsand quo ofthe follow element rum requirement stipulate report financial operating risk article incorporation internal audits shareholder represent share nominal compliance officer value ofat million swiss franc request safety health environmental protection placement item agenda department annual general meeting corporate sustainability committee later day date ofthe meeting scientific ethic advisory group seag issue relate genetic genetic engi change control defensive measure neere establish article incorporation contain provi year blackout period impose sion mandatory bid rule swiss law senior employee prohibit apply trading company stock follow changeofcontrol clause blackout period effect component remuneration base roche january february nes terminate event ofan acqui april april sition vest period restriction pre july july exist award removedso october october option immediately exercise blackout period change chair man board director circumstance warrant board director hold total meet ing board committee meet fol httpwwwrochecomhomecompany low comgovhtm presidium board director httpwwwrochecomhomecompany nomination committeefive meeting comgovcomgovbylawshtm audit corporate governance commit httpwwwrochecomhomecompany teefour meeting comgovcomgovartihtm business report corporate governance information policy compliance officer provide article incorpora tion corporate notice publish compliance officer commit ensure swiss official gazette commerce schwei roche corporate principle consistently zerische handelsamtsblatt daily comply roche group newspaper designate board director serve contact person shareholder basler zeitung finanz und wirtschaft lagefi employee customer supplier general letempsneue zrcher zeitung public issue relate implementation compliance principle employee roche report halfyear fullyear result party aware violation business report publish print online ofroche corporate principle bring format medium event addition attention oftheir manager supervisor report thirdquarter sale figure publish compliance officer andrea greuter year april octobercurrent date ofpubli direct phone number cation available english german disclosure treat confidentialemploy internet ee disclosure penalise relevant information documentsinclud company sobut immune ing medium release presentation prosecution legal violation com analyst investor conference avail pliance officer submit regular report audit able english german internet corporate governance committee publication order email fax telephone baselwebmasterrochecom tel fax contact address investor relation f hoffmannla roche ltd investor relation corporate finance basel switzerland tel fax additional informationincluding detail spe cific contact personsis available internet nonapplicabilitynegative disclosure expressly note information contain mention nonapplicable omission construe negative declaration according requirement swx corporate governance directive include commentary httpwwwrochecomhomecompany comgovcomgovartihtm httpwwwrochecomhomemediamedeventshtm httpwwwrochecomhomeinvestorsinvcontacthtm business report responsible sustainable management responsible sustainable management sustainability integrate index djsi world dow jones stoxx approach sustainability index djsi stoxx improve position roche meet roche strive create sustainable value ftsegood criterion remain member major stakeholderseconomicsocial environ ftsegood index seriesthis clear sign mental progress interdependent influence recognition ofour effort area company create economic value resource active commit ment society environmentat networked structure firm footing time business success feasible intact environment society embrace corporate sustainability committee csc achievement innovation establish corporate sustai nability charter adopt roche corporate sustainability hallmark roche core busi executive committee board director nessafter allour corporate strategy research charter describe mission context base corporation nature longterm composition procedure ofthe corporate sus give research development cycle tainability committee committee draft decadeswe accept associate risk order coordinate strategy sustainable develop develop innovative diagnostic product ment report effort progress medicine help save life alleviate area responsible develop sufferingthis important amend corporate guideline corporate contribution societyin roche select sustainability committee authorise appoint inclusion dow jones sustainability world crossdivisionalcrossfunctional expert group develop review position statement rule information charter find wwwrochecomensustcommcharterpdf corporate sustainability committee report directly chairman ceo submit regular report board ofdirectorsaudit corporate governance committee networked structure ability rely require expertise line functional manager ensure firmly embed organisation enjoy support senior management promote integration sustainable develop ment group operation march roche corporate executive committee appoint csc core team pierre jaccoudchairsecretary corporate executive committee head ofthe chair mans office peter bierihead ofcorporate audit business report responsible sustainable management andrea greutercompliance officer erwin schneiderhead ofcorporate finance peter heerhead ofpublic affairs accounting control gottlieb kellerhead ofcorporate service peter schnurrenbergerhead ofcorporate safety human resource health environmental protection horst kramerdelegate ofthe diagnostic dianne youngsecretarycorporate finance division investor relation karl mahlerhead ofcorporate finance investor relation bruno maierhead ofcorporate law patent deal risk christopher murraydelegate ofthe pharmaceu tical division ofthe business planthe material risk rolfschlpferhead ofcorporate communica achieve company goal identify tion assess group risk management team innovation mindset promote sustainability roche working number year professor ulrich steger director forum corporate sustainability management imd lausanne switzerland professor steger prompt imd roche start work forum corporate sustainability management roche member thoroughly analyse link company core strategy sustainability roche management want bet ter understand companyspecific driver sustainable development key find roche safety health environmental protection risk closely tie business model sustain management research corporate culture ability generally roche benefit cooperation history roche familyowne firm imd play important role tradition commitment demand researchbased health roche pledge demonstrab care company steadily increase issue ly present company found cost explosion healthcare access medicine alive roche today secondly roche stand transparency clinical trial example competitor account level innova change dynamic healthcare sector tion sharp focus develop novel approach cooperation hope business automatically result sustainable business practice model bring closely line thirdly management professional thorough demand business sustainability particularly way link business model sustainability area abundant example roche seek innovative simply pragmatic solution information imd wwwimdch business report responsible sustainable management date total trial register beat widler head global clinical quality assurance roche roche begin make information clinical trial available publicly come debate surround clinical trial transparency prompt roche create desire open communi cation quickly unbureaucratically want reinforce confidence public patient clinical trial evaluate internal option decide build registry manage independent company centerwatch roche present ie end feedback inside roche outside study enter registry positive visitor week third ongoing complete autumn expect private user instance patient include study like find clinical trial result study register ongoing trial phase ii receive initial regu experience project latory approval october roche lead m pleasantly surprised ve see project manage complete study registe implement quickly efficiently registry red regardless outcome public important patient public large support number effort undertake feedback receive project roche ensure colleague team internet site register trial country fast clear overview access clinical trial corporate sustainability committee ciate factor define roche position involve risk assessment process regard value responsible assess socialenviron mental ethical risk identify roche complie ethical standard roche confident institutionalisation sustainable core ethical value com roche employee commit comply pany necessary precondition effective e relevant localnational internation approach al law roche guideline legislation standard come year key area sustainable base roche corporate principle development define relate pri roche directivesguideline marily animal experimentationsclinical study regulation comprise roche code ofcon new technology nanotechnology ducta ofa specially developedinteractive roche undertakes continually evaluate asso computerbase learning program cover business report responsible sustainable management standard deploy worldwide hier prompt objective thing archical levelsince issue ofcrucial impor information mean help patient consulta tance vital ensure roche tion physician find clinical trial employee actively participate programme participatefor anotherpractise roche company united stateswhich physicians healthcare professional compliance programme exempt able obtain balanced overview clinical programmefor information trial result information find code conduct httpwwwrochecom wwwrochetrialscom enhomecompanycomgovcomgovcondhtm find roche corporate principle ethical responsibility research internet wwwrochecomenhomecompanycom development govcomgovcondcomgovprinchtm daytoday work develop new medi corporate sustainability report address cine diagnostic testsethical issue arise societal issue context enforcement roche take clear position policy procedure address fraud research human subject bring briberycorruption track report case attention employeesfurther information violation follow necessary mea find wwwrochecompagesdownloadssustain sure take pdfposhumsubrespdf global ethic liaison office establish research activity roche meet drive systematic resolution rigorous ethical standard issue open roche employee query submit issue range innovation key success business trial plan design datum protection compensa endeavour research imply responsibility tion patient clinical trial problem groundbreake science inevitably entail satisfactorily solve risk opportunity set high liaison officethe case refer internal ethical standard research activitiesroche bodywhere necessaryan external advisory group issue clear directive govern ethical consultedfurther information roche consideration observe genetic research framework discuss resolve ethical issue clinical trialsanimal experimentsetcwe human subject research wwwrochecomsust provide scientist decisionmake tool resethissclintpdf back targeted continuous training eventsroche company industry thesto set external ethic body responsible animal experiment advise support internal research depart ment roche researchbase healthcare compa niesthe appropriate responsible use ofanimal experiment essential biomedical clinical trial protocol registry researchand majority ofsuch experiment clinical trial result database prescribe authoritiesfor past year roche gathering datum glob believe roche ethical obligation al research companythe aim dis ensure scientifically clinically relevant datum cuss type scale project clinical trial available research manager andtogether themto seek publicin early roche company way optimise use animal research industry set clinical trial protocol reg jeopardise quality ofthe work istry independent host idea safety ofpatient business report responsible sustainable management past year datainclude figure biodiversity bioprospecte research site contractual partner animal roche recognise issue biodiversity experiment rat mice retention traditional skill grow nonhuman primatesroche simply importanceparticularly lowincome country source difficult experiment con roche support principle un conven duct company take tion biological diversity ofroche global responsibility themwith aid innovative position global roche statement biodiversity technology biomarker company find wwwrochecompagesdownload endeavour reduce number sustainpdfroposbiodivpdf experimental animal usedthis costeffec tive approach nanotechnology public concern use ani mal scientific research seriously roche roche track new technology closely assess endeavour set high ethical standard help improve productsser thusby end ofall roche research centre vice processesnanotechnology new accredited aaalac association technologywe study ethical social assessment accreditation laboratory implication ofthis form ofminiaturisation animal care international large roche potential practical application expert research centre certify group corporate sustainability com futurefurthermoreall contract party mittee roche currently draft position include clause stipulate aaalac paper nanotechnology com requirement meet roche reserve plete early right conduct audits verify care use ofanimal roche group stem cell research intensively coordinate futurea steproche appoint person organ roche generally interested relevant scientific ise group training activity areathese developmentsfor instance stem cell research effort back global networkfur application currently roche ther information find wwwrochecom engage activity area therapy homesustainabilitysusressusresanimhtm replacement tissue stem cellsnor employ method technologiesmore roche decide engage human genetic bioethic clone reproductive purpose the roche assist recognise inter roche develop clear position stem cell national expert draw roche charter research relate application clone geneticsand work find wwwrochecomsustposstem independent bodythe science ethic advi cellspdf sory group seag regular meeting hold seag advise roche matter relate charter particular genetic general marketing exampleseag address issue relat ing ethicsbiomarker genomicsformulate roche establish implement number recommendation issue review ofinternational guideline design use correspond position paper submit advertising material website struc rochefurther information seag find ture event globally applicable rule wwwrochecomensciethcharthtm ensure use ofadvertise material complie business report responsible sustainable management legally valid regulation roche regularly review quality standard information wwwrochecomensusethguidel system constantly develop themthis review prompdf roche go development task range conduct legal provision instance recognise internal audits systematically monitor pro pharmaceutical research manufacturer duct quality analyse trend promptly re ofamerica guideline directtoconsumer ad ponde complaint customer vertise guideline come force roche reinforce trai ning programmesmoreoverwe implement protection counterfeit european marketing code european federation pharmaceutical industriesassocia counterfeit pharmaceutical diagnostic pro tion efpia roche purpose duct violate property right jeo draft number internal guideline pardise health patient undermine general manager roche company confidence health system roche combat responsible implement infor forgery rigorouslyin roche establish mation wwwrochecomenhomesustainability global policy outlining measure place susethsusethmarkhtm prevent counterfeitsin addition technical mea sure relate design labelling packaging focus primarily monitor market ensure product safety agree business partner clearly define arrangement audits forgery roche product effective discoveredroche immediately inform autho allthey safeat roche large number ritie ifappropriate general public people work area drug safetywhere seek protect patient adverse drug reac tion identify effect early possible classify term severity important undesi rable effect headache example harmless comparison disease treat ega lifethreatening condition cancerin casethe benefit ofevery medi cine weigh risk involve employee work area drug safety systematically monitor roche product worldeven registeredin staff review assess total report ofadverse drug reactionsonce undesi rable effect identify product information supplement accordingly conjunction responsible authority roche commit comprehensive quality management system ensure qualitysafety efficacy medicine diagnostic test roche standard base specification lay recognise international body healthcare authoritieseach employee responsible ensure guideline fully comply area business report suddenly realise life hang thread business report tale lifesave diagnosis heart failure mohinder pratap johar easy man admire eats healthily make sure get physical activity lead busy life thing turned differently start feel tired short breath instead usual fit self doctor diagnose high cholesterol medication not help fortunately happen time elecsys probnp cardiac test launch mohinder native india test renowned delhi heart lung institute result show alarm rise blood level protein produce heart indicate mohinder suffer heart failure condition heart muscle long pump efficiently examination reveal mohinder life hang threadthree artery supply blood heart clog put risk massive heart attack immediately undergo bypass surgery meantime mohinder resume virtually normal activity prefer dwell happen heart test diagnosis get fast accurate diagnosis matter life death minute elecsys probnp determine person shortness breath heart failure early stage disease conventional test fail help prevent disease promote early treatment help save life business report dialogue stakeholder listen learn analyst discuss performance gain stakeholder feedback expectationsroche con tinue ensure market player receive regu term stakeholder refer individual lar update business strategy business group individual influence performance roche commit transparent interest company ability achieve fair reporting available simultaneously objective include particular market playersa outline communi employee patient medical scientific cation policyfurther information find personnelinvestorsthe authoritiessupplier wwwrochecomcommunicpolepdf feedback mediaour relationship stakeholder performance importantand rea base general commitment set son participate number investorrela corporate principle gear specifi tionstargete external survey include cally concrete need ofboth side thomson extel institutional investor research group surveysa additional survey customer website annual report thomson extel survey roche investor rela roche strive excel areainclude tion team pharmaceutical division customer relation happy receive award place ahead competitor positive feedback customersin particular information investor relation find patient medical specialistsbut regard wwwrochecomenhomeinvestorshtm complaint important source information possible improvement aim respond employee employee organisation quickly need ofour customer develop sustainable relationship communicate roche believe business depend patient benefit product talent performance dedicated employee service follow channel crucial factor success recruit healthcare professional pass patient motivate develop retain outstanding view productrelate website people effort promote open wwwaccuchekcom wwwbonepaincom twoway communication company patient organisation foster cooperation crossdivisional cross border team key element human holder share nonvoting equity resource management set roche security investor employment policy information wwwrochecomenhomesustainabilitysussocsus interest cultivate close trans soccommcomgovemphtm parent relation shareholder holder share nonvoting equity securities finan roche employment policy statesamong cial analyst help decide future focus thingsthat right employee roche expect keep datewe engage employee organisation roche ongoing frequent substantive dialogue ready work open dialogue legal shareholder numerous channel employee representative country management roadshow broker confer operate major ence visit roche teleconference roche restructuring reduction personnel organise event topic key interestduring management meet investor business report dialogue stakeholder important stakeholder significance roche employee approximately sale revenue roche compensation employee billion swiss franc salary roche provide employee country attractive job holder share trust holder share nonvoting equity security roche strategy nonvoting equity security management important success billion swiss franc profit pay form dividend profit invest longterm increase company value patient medical product sell country instrumental improve quality scientific community life prolong life year invest billion swiss franc professional association research development new product service patient participate clinical trial benefit late drug development public sector roche pay taxis amount million swiss franc make considerable contribution finance state infrastructure programme addition relationship oftrust cooper continue develop provide effi ation management employee repre cient solution health problem safeguard sentative local level roche europe environment receptive research forum employee representative open innovationwe consider different country meet member roche important engage dialogue political de management prove sound basisthe cisionmaker legislator regional roche europe forum represent approximately national level seek contact employeesieabout ofthe workforce counterpart european interna roche record employeesmem tional stage direct contact hand hand bership oftrade union degree ofunion effort industry organisation isation individual affiliate accord local estimatesabout quarter ofroche employ society nongovernmental organisation ee member ofa trade union slightly interest group represent form employee organisation roche cultivate longterm cooperative relation ship nongovernmental organisation authority public sector ngo group play active role partnership primarily contribute human roche strive maintain relationship resource knowhow less extent relevant health authority player public fundingthe follow selection sector long term strategically drive list organisation initiative transparent active political legal roche work involve environment highly complex govern international regulatory intricaciesour goal national international business industry involve early stage political association process relevant businessso world business council sustainable develop intervene proactivelywe present posi ment wbcsdroche found member tion transparently primary aim ensure wbcsd involve working business report dialogue stakeholder group organisation supplier business partner business charter sustainable development icc international chamber commerce manufacturers specific intermediate roche endorse charter found signa product development roche involve tory commit observe roche stan responsible careroche regard responsible care dardsthey cover compliance pro important aspect ofsustainable development cedure monitor observance ofthese dedicated put practice regulationswe particularly close watch world environment center wec roche supplier approach workplace safety active member earlys occupational hygienepollution waste manage global environmental management initiative mentin waywe aim ensure sup gemi plier service provider follow legal global business coalition hivaid requirement principle ofsustainabil pharmaccess foundationcareprogramm ityroche recently release set ofguideline gov european coalition ofpositive people ecpp erne relationship supplier service development disaster relief organisation providersthese guideline set formal term international committee red ethical requirement company cross national association purchase product service find information subject wwwrochecom extend list main stakeholder contact ensusethguidelsuppdf organisation roche member find internet wwwrochecoman homesustainabilitysussocsussoccoopsussoc coopinthtm business report dialogue stakeholder report view stakeholder sustainability report focus verdict follow overall panel feel information requirement stakeholder roche carry substantial detailed important feedback commendable piece work sustainability account improve finetune report report demonstrate roche real commit report ment sustainability give evidence clear obli gation comply gri standard provide roche sustainability report receive num example case study good work ber award nominate carry member company part european sustainability reporting award world detailed examination report award ceremony schedule february yield recommendation improvement sub fact successfully complete assessment sequent report include integration risk process renew inclusion dow jones management detailed objective performance sustainability index ascribe figure great transparency crossreference report improve certain aspect report sustainability roche business model account feedback stake description conduct stakeholder group holder detail evaluation panel improve readabilitystructure feature wide range expertise utmost implement improvement representative ngos investor confident present report come expert field communication governan close meeting stakeholder information requi ce corporate social responsibility audit rement business report feel regained control disease give huge psychological lift business report herceptin breakthrough woman herpositive breast cancer maggie duke specialist hygienic engineering vevey switzerland diagnose breast cancer small hard painful lump find breastafter removal lump maggie begin treatment chemotherapy radio therapy hormonal therapy unfortunately year cancer spread bone liver test show maggie herpositive breast cancer aggressive type require special care treat combination chemotherapy herceptin drug design specifically herpositive cancer month begin treatment herceptin maggie outlook improve dramatically give huge psychological lift renew hope lead active life start treatment herceptin seven year ago maggie carry normal continue work travel participate muchlove sport thank health energy regain able participate longdistance cycling event help raise fund cancer research therapy breast cancer overproduction protein result fastgrowe tumour respond poorly chemotherapy herceptin trastuzumab specifically target shrink tumour harm healthy cell advance early disease herceptin improve survival maintain quality life woman herpositive breast cancer business report commitment employee successful business eastern european regionleading create new job crease headcount overall increase number new position grea recent yearsroche expand fast test research development market competitorsthis lead increase ing sale roche group hire total headcount business area regionsin new employee order fill vacan roche group create total new cie create new jobsbeside retain number employee personnel cost division change personnel cost change roche group pharmaceutical diagnostic million franc number employee region change europe switzerland north america latin america asia japan africa australia oceania jobsan increase headcount increase talented motivated employeesit impor diagnostic division tant view goal increase sale pharmaceutical divisionofwhich genentech profit effective approach attract account forin roche spend mil e new talent httpcareersrochecom lion swiss franc employee remuneration increase million swiss franc previous yearthese figure exclude impact employment policy ofa oneoffgain return ofpart ofthe chugai employee pension fund japanese govern employment policy lay require ment ment human resource management roche group meet establish large number ofnew position create right obligation roche employee region europe north america regard company information sale grow fast average topic available wwwrochecomenhome instance see found ofnew company companycomgovcomgovemphtm business report commitment employee roche popular employer climber popularity employer europe record employee satisfaction conduct labour market highly qualify talent survey indirect indicatorsillness pharmaceutical industry extremely competitive rate departure initiate rochea glob roche considerably improve al illness rate clear indication global presence market employee enjoy good working condition feel effective attract outstanding employee comfortable work roche approach twopronge employer total attrition rate ofpermanent staffwa brand underscore key advantage number regret loss roche global employer industryand employeesthe proportion ofdepar introduction global erecruiting ture qualified staff high sale launch internetbased global recruitment administration please tool enable candidate view current low number departure qualified staff vacant position glanceapply job online research production register global local talent marketing poolsthe tool candidate register apply employment demonstrate overall roche count past year roche achieve demonstrable stable pool motivated employee risk competitive advantage recruiting achieve project result business fast efficienta well selection critical area result significant number grow number qualified external appli regret loss regard minimal fluctuation employee regret loss ie fluctuation initiate roche employee cant possibleandlastlytransparency inter performance culture roche nal applicantsroche come considerably close achieving goal door roche performance management em unique combination system phasise key management instrument gen end ofall know vacancy worldwide erate sustainable add value rochethe link viewable websitethis percentage corporate goal daytoday busi increase ness carry management employee forge goalsette managementin pro roche company num cessthe performance ofmanagement staffis mea ber ofprize top ranking attractive sured term contribution sustainable employeregroche genentech usain value creation companyall senior man germany good employer switzerland good ager roche share common goal sustainably employer woman spain good employer increase enterprise value measure australiaroche vote high opac operating profit cost ofcapital business report commitment employee door roche roche vacancie glance begin roche launch global personal datum cv register career internet site httpcareersrochecom roche talent pool soon vacancy come show vacancy group glance roche contact potential candidate date country link site profile match requirement job que mean end tion roche employee apply job opening vacancie roche view online site way roche career internet site unique contain information roche individual instrument industry support group country affiliate vacant position growthdriven corporate strategy interested apply job roche target group standardise regular feedback development review formance managementwhich originally cornerstone performance management senior management approx managerswa career development staff promote high extended include large population specific management position basis oftheir leader critical segmentsin roche refine ship quality actual performance groupwide standardised database integrat ed system provide goalsette agreement succession management process global great transparencythus facilitate compar key position establish review ison controlit provide broad factual regular interval succession planning carry basis decision developmentpromo yearfor group tion transfer manager group divisional level talent situation roche encourage affiliate goalsette group average model performance management regular succession candidate key position com feedback performance placealtogether pare bestprac workforce define goal set tice range candidate positionwe objective regularly receive feedback confident focus performance mana performance gement produce sufficient number internal candidate ensure high standardthe risk ofgap key position talent management development cause negative impact business result roche people leave negligiblein case ofvacancie business success rochetoday future position fill short time depend effort large number moti process global succession planning vate highly qualified employee man talent identification take ager characterise performance culture adapt countriesin ofroche roche high degree ofindividual responsibility affiliate systematic succession planning training management development total hour invest trainingstaff development million million training time employee day hour day hour business report commitment employee process place affiliate roche introduce leadership charter programme place systematic identifi competence model manager company cation development oftalent adapt divisionsthis model base essential competency man employee development roche take form ager roche possess give roche primary tool process development manager consistent view expect planin training development plan term ofmanagement competency describe concrete development prospect step achievement new execu agree roche employee tive development programme senior manage addition continue educationthe plan call ment roche begin target strategic posting oftalente employee abroad group programme manager grow number project assignment job company rotation effort deal efficiently peak compensation benefit work volume employ employee temporary basis end compare remuneration policy adopt endin additionwe cur design support value creation reinforce rently training apprentice offer roche culture performance innovation prospect ofa career future deliver remuneration meet employee roche employee participate roche connect lisa teverson group head compensation benefit exactly roche connect programme function roche connect share purchase programme give roche employee option acquire roche nonvoting equity security know genussscheine switzerland discount chan ce participate company growth pro gramme start offer employ ees country worldwide great success give short time span programme step roche connect launch implement programme country relatively easy cur participate programme rently offer plan country like usa china soon roche connect launch country legal requirement complicated permanent employee participate world continue check feasibility especially wide percent employee china hope soon able include offer decide pro employee country roche connect gramme develop temporary achieve goal lot work employee share generally consider longterm investment business report commitment employee need futurethe award include change pension plan roche long termthe new incen employee switzerland tive programme executive key manager approve end ofparticipant receive stocksettle stock appreciation promote diversity workplace right option acquire genussscheinedepen ding depend tax efficiency mark roche place high value diversity seek notable change particularly usa benefit integrate difference incentive traditionally base american spective group activitiesroche employ depositary receipt instead genussscheine people country affili incentive entitle participant worldwide ate head general manager local base growth value country trend risingthe affiliatesman genussscheine involve agement teamstooboast consistently high pro immediate financial interest increase com portion staff local regiontalent pool pany value worldwide feature grow percentage ofperson nel variety ofcountrie continentsthe follow award employee corporate center come roche connectthe employee stock genussschei countries ne purchase planroche receive exter nal recognition employee equity pro roche aim attractive employer grammesthe global equity organization geo women man reason promote lead international organisation promote diversity staff fourth year share ownership employee award roche row roche recruit woman award creative innova menwoman account entire work tive design company force contrast employeesthis time award receive employee leave roche woman new roche long term incentive programme manager roche femaleamong make award judge praise way identify global key position mainly global roche identify address difference senior middle management ofall incum prior incentive plansand change compet bent female itiveaccounte tax environmentsto arrive new global programmewith launch ofthe respect worklife balance key con plan argentina country cern rochethis follow different path depend include roche connect bring total ing country base straightfor number country plan offer ward principle instance roche support membership plan continue grow employee enable deliver optimal significantly reach vs formance accordance family obliga indication roche tionsthere variety ofworke arrangement employee identify company roche special workingtime eg parttime employment flexitime sabbatical parental leave number ofnew benefit plan change exist man woman childcare facility ing plan approve past year arrangement help reconcile need woman percentage total workforce percentage woman management position number woman position percentage woman candidate management position business report commitment employee career familyall measure comply local legislation case far legal requirementsroche offer option parttime employment requirement ofthe job permitapproximately ofour current employee work parttime basis man respect human right roche support respect human right defi ned united nations apply princi ple consistentlythe compliance officer monitor policy roche groupand serve contact person employeesfurther infor mation topic find wwwroche comenhomesussussoccommhumhtm violation employment policy principle report roche executive committee compliance officer soon violation knownmeasure take deal appropriately business report commitment society brief gain involvement society key prerequisite longterm orientation researchbase company roche operate success business regard specific accord business model focus aptitude find innovative efficient solu create sustainable add value principal tion unmet medical need principal stakeholder maximise shortterm contribution societywe contribute substan roche international committee red cross develop partnership gille carbonnier head private sector relation icrc geneva switzerland roche international committee red cross icrc initiate new partnership october involve roche seven swiss company icrc develop longterm strategic partnership tackle social issue globe year roche support icrc fin ancially provision material eg roche icrc work drug service agreement combat aid roche icrc cooperate area cooperation make sense project provide assistance victim question protect victim war tsunami catastrophe december natural catastrophe aid occasion roche send icrc antibiotic ensure safety people icrc medicine treat people employee work country large africa roche help area roche icrc work instance put touch main player fight aids west africa instance exchange idea icrc bene fit substantially knowledge roche employ partnership develop go forward ee deal medicine late april near future examine way reinfor icrcs lead pharmacist come basel cing link possible area personnel able drug manufactu management risk management logistic s red sterile condition important lot potential cooperation icrc purchase drug world roche icrc want certain buy good quality include counterfeit deleterious health business report commitment society tially create value main stakeholder saharan africathe price reduction hiv pro group seek maintain enhance ope tease inhibitor roche apply rating environment conducive innova people hivaid world tion strategy implement roche improve global additionroche maintain support num access healthcare include ber ofactivitie closely bind develop clear patent pricing policy specialist skill particular business model aim facilitate access hiv medication societal contexttoowe attach importance poor people world cooperate reliable partner focus people worldwide live limited number sustainable effective pro hivaid ject roche position social responsibility work partnership commit govern currently undergo review process mentsnongovernmental organisation oth release er party share similar goal undertake research development develop new antihivaid medicine ensure access healthcare improve exist one worldwide promote education training knowledge sharing roche important contribution society lie donate technical expertise area ofindus research development production trial development ofmedicine andin particular innovative costeffective solution unmet ofantimalarial order support develop medical needsaccordinglyroche focus area ment distribution new drug combat company create genuine sustainable malaria add value result special expertise role healthcare system corporate cul find detailed information ture nurturedby develop main brochure commit make differencepub taine innovative solution collaboration lishe p information competent local partnersit possible pro find wwwrochecomcommdiffreppdf vide last assistance design deal wwwrochecomenhomesustainability cause disease base simple susmedhtm wwwrochehivcom methodsthis apply especially programme benefit group develop coun amplicare programme roche diagnostic try define united nations supply subsaharan africa include south poor need great africa country classify un casesaccess fundamental developedcountrie hivb load test food drinking water basic low possible price medical care guarantee fight hivaid example programme amplicare programme work medicine focal point sustain laboratory clinic provide tailor able developmentthe distribution ofthe hiv solutiondetermine product protease inhibitor invirase viracept affordable suited region questionwe regard exemplary roche policy roche deal pharmaceutical price offer medicine noprofit price roche cost reflect range outlaysinclude basel develop country sub testsinstrumentsconsumablestraine logis business report commitment society tic service offer vary accord tradition commitment sponsorship customer differ need depend donation dividual requirementsthese cost percent standard price owe area expertise corporate amplicare initiative cooperate culturewe mainly involve usbased william j clinton presidential humanitarian social project focus foundation develop world promote sciencemedicine professional detail brochure commitment developmentofyoung scientist area care globe information contemporary art culturea available wwwrochecompagesdownload local community environmental project sustainpdfrochehivbroepdf difficult ascertain sustainability monetary product donation dona tion kindroche decide publish detailed figure monetary value ofit activi tiesin roche donation go humanitarian social project donate fund support advancement sci ence educationnearly donation go project contemporary culture art community environmental project onequarter donation kind threequarter form financial support roche make political donation clearly define exceptional case line prevail legal ethical standardssuch donation politi cal organisation support condition favour innovation individualspolitical donation account donation sponsorship expenditurein roche begin col lecting datum impact monetary product donation result million patient benefit directly donation especially humanitarian social nature roche agree donate million pack tamiflu world health organisation detail p year roche maintain contact business report commitment society ngo impressive proof policy authority aid organisation organise work reliable partner fulfil emergency assistance conjunction inter commitment society people national relief bodiesin country affect enjoy support roche tsunami roche supply medicine donation promote science educationcom treatment people find munity environmental projectsand culture information roche drug donation policy wwwrochecompagesdownloadssustain provide disaster relief roche supply know pdfdrugdonpolpdf andwhere appropriateit product service competentlocally root aid organisa ofthe founder familyroche tion order alleviate acute emergency long intensive relationship contem decision undertake kind action lie porary art culturein particular music local affiliateboth beginning fol demonstrate tinguely museumwhich lowing tsunami disaster asia donate maintain roche visu earthquake pakistan october roche al arts architecturethe rochenjazz project assess situation relevant example ofa new kind ofactivityset general manager touch local aim enable roche company stage support roche research foundation found roche rrf support total million swiss wwwresearchfoundationorg provide support young scientist franc pay project conduct basic research biology application swiss national medicine science foundation rrf country important institution support young scientist roche organ transplantation roche donate million swiss project europe south research foundation wwwrotrforg franc tenyear period america united states independent research foundation australia foundation money foundation support grant totalling support innovative research project million swiss franc field organ transplantation roche foundation found roche total million swiss franc anemia research undertake research new pay seven project switzerland wwwrofarorg approach treatment germany uk usa anemia application genentech foundation support educational total million dollar donate biomedical sciences communitybase organisation project wwwgenecomgeneabout san francisco bay area usa communitygfbs business report commitment society global roche employee aid walk global roche employee aid walk sponsor walk involve roche employee world principle simple effec tive employee register walk encourage colleague friend family member sponsor roche double sum collect employee money donate support aids orphans malawi africa half million child ren lose parent aid million people world infect aids walk take place roche hiv million live subsaharan site basel switzerland nutley palo alto africa malawi approximately adults usa year employee take infect hiv malawi classify event walk total develop country peaceful swiss franc aids orphans malawi politically stable country stability mean site participate num project forward roche employee plan ber take increase tenfold time ne long term longterm planning essen employee join donate approxima tial bring sustainable improvement tely swiss franc child malawi orphans situation donation invest directly project held bureaucracy april seven successful roche fund manage partner organisation roche raiser travel malawi hand european coalition positive people ecpp donation use return thank roche donation organisation convince donation able build orphanage directly benefit orphan participant say child receive food clothing donation help provide hope future benefit school education child business report commitment society series concert partnership local jazz club series intend primarily roche employee family open interested member public wellit design promote local jazz performer composerswwwrochenjazznet ofcontribution employee augment ed roche contribution case coordinate roche employee action charity trust react found trust headquarter basel future co ordinate emergency measure longerterm recon struction programme distribution fund collect aids walk business report business report avastin open new era cancer therapy hamish hutchinson diagnose advanced bowel cancer january notice abdominal discomfort christmas exploratory surgery establish extent cancer affect hamishs colon successfully remove surround tissue contain secondary tumour hamish start chemotherapy february session avastin add treatment regiman august cycle chemotherapy plus avastin ct scan show clear cancer treatment stop hamish feel live normal life return work anesthesiologist hospital tunbridge wells uk tell advanced cancer come huge shock hamish family reaction total disbelief support wife helen please cancer daughter clear doctor pollyanna victoria play big role able return work recoverythank say hamish give therapy avastin bevacizumab open new era cancer therapy offer patient well outcome great hope standard chemotherapy treatment metastatic colorectal cancer avastin antiangiogenic drug demonstrate anticancer benefit inhibit growth network blood vessel supply nutrients oxygen cancerous tissue shut blood supply essential growth cancer spread part body business report safety health environmental protection corporate policy field safety health environmental protection apply health environmental protection group division eco delegate support organisation con roche gear corporate policy field ofsafe crete projectsfurther information find ty health environmental protection wwwrochecom enhomesustainabilitysusenv iso environmental management system susenvpolhtm policy base experience go year commitment sus thank professionalism hard work ofthe tainable development enter staff involve roche company fine context charter international cham significant infringement safety ber ofcommerce iccthe world business coun health environmental regulation cil sustainable development wbcsd evidently accomplish resort chemical industry responsible care programme rigid management system consume consider roche guideline assurance safety able resource intention attain iso key figure investment millions chf operating cost millions chf occupational accident workrelate fatality workrelate accident million work hour workday lose workrelate accident total number workday occupational illnesses occupational illness million work hour workday lose occupational illness occupational accident contractor firm workrelate accident million work hour contractor firm number transport accident road transport accident metric ton transport road x x total energy consumption tjyear co tyear tyear x tyear vocs tyear particulate matter tyear water consumption million cubic meter year toc tyear heavy metal tyear chemical waste tyear fulltime personnel total number employee base cefic health safety environment report guideline november business report safety health environmental protection andor emas certification centrally management systemcorporate safetyhealth approximately local manufacturing compa environmental protection cse carry ny represent oftotal production volume systematic groupwide audits company chemical production volume site date nearly decide discretion adopt complete year review total approachbase exist corporate policy production facilitiesdistribution centresresearch site office building audit coun auditing triesonce againthe result good safetyhealth environmental protection audits audits focus primarily safe envi audits key element roche ronmentally responsible behaviour ofemployee energy consumption reduce percent palo alto california keith sonberg team busy translate roche energy con servation policy action result low energy consumption low cost keith sonberg team proud awardwinner ecompetition roche competition sustainabi lityrelate idea award project reduce energy consumption laboratory fume hood saving come dollar year fume hood think competition laudable idea say sonberg clearly show roche mana gement aware sustainability environmental issue addition fume hood project sonberg rudolf schwob roche corporate safety health team palo alto develop imple environmental protection explain criterion mente comprehensive sustainability programme project award competition prize range energysave light bulb green count project impact engineering employee training environment budget important project implement result impressive past year roche site energy consumption palo alto site reduce percent water consumption roche employee give chance parti percent recycle rate construction waste cipate competition submit project high percent sonberg say improve sustainability work environment pride roche list right dow time ecompetition hold follo jones sustainability index goal remain wing competition total pro environmentally friendly economically effective ject submit select socially accountable future jury prizewinner business report safety health environmental protection workplacea technical safety number ofoccupational illness million work process plantsthe risk ofdust explosion ing hour increase number ofwork production formulation hazard ing day lose result occupational illness handle biologically active compound line growth ofthe company term potentially contaminate diagnostic instrument headcount number site produc increasingly important aspect ofrisk tion volumeenergy consumption increase assessment absolute figure efficiency improve relation sale revenue number employee systematic audits ofstrategically important suppli true volume greenhouse gas er manufacture chemical intermediatesfinishe emission emission air water product exclusive equipment part declineda volume ofchemical waste perform ofthese audits complete past year scope reporting year reporting cover roche group pharmaceutical diagnostic divi sion chugai genentechas scope ofthe reporting previous year key figure directly comparable absolute term owe different system boundary possible early year bulk datum collect november basis month extrapolate entire year cost accident incident fullyear datum collect detail safety health environmental protection wwwrochecomenhomesustainabilitysusenvsus envcarehtm result brief group performance publish sustainability report year successionfor year previously publish separate reportthe group performance describe good trend achieve goal set energy consumption greenhouse gas voc emission point right directionnew target intend spur roche group improve performance report entire group significant damage affect individual environment number occupational accident keep low levelthe business report safety health environmental protection goal progress safety health improvement ecobalance environmental protection indicator record year time roche set target reduce reduction consumption group greenhouse gas emission ieco employee line energysave energy generation halogenate hydrocarbon goal air conditioning equipment chiller annual targetno relevant fine area percent year period energy consumption ecoefficiency expenditure emission volatile organic compound voc safety health environmental reduce percentageabso protection lute value base group sale order allow change corporate structure ecoefficiency enable comparison baseline ecoefficiency important element promo te sustainable development ecoefficient pro owe measure reduce emission duction process conserve resource raw positive trend group sales revenuethe tar material energy reduce impact get set reachedroche environment decrease emission waste determine effort confirm volumesthere positive financial impact improve good result roche quantifie ecoefficiency calculate ecoefficiency rate eerthe eer indicator goal ecological effect expenditure en vironmental area determine mean readily measurable parameter quantitie energy consumption ofsubstance emit waste produce financial figure sale spending ear mark environmental protection high greenhouse gas emission eer great degree ecoefficiency detail wwwrochecomenhome sustainabilitysusenvsusenvcarehtm voc emission expenditure goal roche group purpose graph value normalise sale investment safety health give multipli factor energy consumption x greenhouse environmental protection gas emission x voc emission x operating cost additional objective define total expenditure framework medium longterm millions chf programme reduction roche accident rate ecobalance rar reduction absence overall achieve target ofa improvement relevant indicator record year group ecobalancea criterion establish time compare number yearsfor business report purposeroche employ method ofthe swiss agency environment bafu environmental impact point give ecologi cally relevant parameter emissionswaste energy consumption point add express function number employee past year ratio figure serve baseline measure improvement investment operating cost expenditure roche group total million swiss franc compris investments investment e investment operating cost total expenditure safety health environmental protection ecoefficiency rate eer include chugai genentech sale environmental expenditure environmental damage eer millions chf million environmental damage unit key figure ecoefficiency include chugai genentech include source co emission external energy generation comparable previous year key figure unit energy tj million sale co million sale voc million sale water million sale toc million sale chemical waste million sale es investment area operate coststhe calculation investment take account value con struction project solely purpose egfire extinguisher systemswastewater treatment waste incineration plant portion investment calculate arising project new production facility plantsin investment amount mil lion swiss francs environmental protection million swiss franc safety health operating cost year review amount million swiss francsthis inclu expenditure millions chf business report safety health environmental protection des current spending service personnel accident statistic cost area shein total number roche group employee work fulltime employee roche group roche group expense express employee record statistic proportion oftotal sale workday lose workday record occupational accident record safety health protection occupational accident employee accidentsmillion work hour cefic roche believe important employee work healthy safe work environ rar roche accident rate ment possible safety health committee glossaryexplanatory note wwwrochecoman focus technical activity production homesustainabilitysusenvsusenvcarehtm laboratory workshop introduce virtually roche subsidiary cover employee give site ofhealth monitor programmesmotivate staff increase level physical activity increasingly workplace way provide information healthy nutrition reach employee order help roche begin collect data general prevent potential workrelate problem absence aim discover enhance staff health general initiative cause absence seek possible include offer preventive medicine measure improvement work highly active substance recent pharmaceutical research produce medi cine specifically target biological action fit precisely particular receptor influence target target action effective minuscule quan titie case call highly active compound substance potent patient manufacture essential ensure employee overexposed substance care take contaminate prod uct highly active substance process contain system workplace special emphasis place technical roche industrial hygiene committee con approach ie contain system siste specialist occupational toxicity industrial roche decide build completely new plant hygiene occupational medicine prepare assess meeting necessary technical standard ment hazard pose substance manufacture drug contain highly active sub define exposure limit serve tool stance choose erect new plant toluca derive appropriate protective measure mexico business report occupational accident accident employee roche group figure occupational accident roche deteriorate slightly low level year reviewthe number ofaccident involv ing roche employee rise severity accident ie number work day lose accident result accident increase roche accident rate rar rise addition roche employee total employee contractor firm involve accident ie previous year figure parallel number ofcontractorswho past year work mainly construction sector occupational illness total number ofoccupational illness report increase working day lose result illness year review type illness report year remain unchangedlocomotor disor der continue common problem especially inflamma tion upper extremity cause repetitive movementsillnesse relate use chemi cal limit allergiesthere werehoweverno case ofintoxication incident incident accident significant impact people environment report roche groupowe small number minor incident statistical analysis event virtually impossible human error identify main cause transport previous yearsroad transport account bulk good move follow air transport incident report lorry load pharmaceu tical active substance steal cargo lorry destroy result acci dent roche accident rate rar safety health environmental protection occupational illness roche group recognise case occupational illness lose working day transport mode show percentage road rail sea air inland waterway business report safety health environmental protection environmental protection energy consumption sustainable development imply responsible use resource energyroche set goal reduce energy consumption companyalongside corporate target reduce energy consumption relation sale year additional longerterm goal formulate reduce consumption relation head count period close correlation energy consumption co emissionsa decrease energy consumption lead reduction release ofgreen house gas atmosphere year reviewthe roche group need terajoule ofenergy source natural gas oil coal waste renewable energy electricity district heating fleet vehicle business travel air total run operationsthis figure include energy require run group company fleet vehicle energy consume business travelin absolute termsconsumption rise yearonyearhoweveruse employee actually fall greenhouse gas roche support effort international communityas lay kyoto protocolto adopt worldwide approach control global business report warm greenhouse gas re ponsible groupwide target decrease emission relation sale measure reach trading emission certificate cur rently option unlikely foreseeable future greenhouse gas emission measure accor dance greenhouse gas protocol serve gri standard require account direct emission power generation fossil fuel waste incineration fleet vehi clesbusiness travelwastewater treatment import energy electricity greenhouse gas emission roche consist co power generation direct emission combustion fossil fuel account halfofco outputapproximately ofall energy consumption figure tj joule emission come co result import energy particular electricity roche responsible co emission amount metric ton halogenate hydrocarbon play small role greenhouse gas emissionsthey cool air conditioning installation fire extinguish equipmentin emission amount metric tonsthe global warming potential ofhalogenate hydrocarbon convert co equivalentsuse conversion factor specific contribution anthropogenic greenhouse effect roche group co emission combustion co equivalent halogenate hydrocarbon emissionst co equivalent total sale swiss franc millions co equivalent million franc sale mean global warming potential halogenate hydrocarbon base recalculation conversion factor ipcc halogenate hydrocarbon emission halogenate hydrocarbon inventory safety health environmental protection stipulate intergovernmental panel fall inventory ofthese compound compare climate change ipcc add total previous year illustrate progress quantity ofco emission implement guideline roche climate strategy prescribe measure greenhouse effect roche contribution low emission area close link power generation co output mean calculate roche exact contribution energy save measure automatically lead greenhouse effect express co equivalent reduction co emissionscorporate guide million franc sale greenhouse gas emis line exist relation use halogenate sion sale serve benchmark hydrocarbon cool system outline result value ofrepresenting improve gradual phasingout use ment co emission tyear natural gas oil coal waste import energy fleet vehicle business travel air wastewater treatment total co business report safety health environmental protection waste volume waste chemical pro duction amount metric tonsofwhich metric ton incinerate rest include inert substance incineration residue slag ash sewage sludge deposited landfills waste byproduct metric ton residual substance cycle total general waste come metric ton metric ton construction wastethe majority ofwhich deposit landfillsa total metric ton ofgeneral waste deposited landfills incineration landfill construction debris total landfille total recycling business report general waste figure tyear chemical waste figure tyear incineration landfill total valorise general waste metric ton year roche group incineration landfill construction waste total recycling chemical waste metric ton year roche group incineration landfill total valorisation safety health environmental protection contaminate site responsibility originator industrial activity leave trace subsoil soon contaminate site bring atten site question substance installation tion authorise study require evaluate chemical manufacture process associate risk depend outcome step leave residue soil addition nature containment necessary remediation site synthesis pharmaceutical substance result subsequently take process conduct close desire substance byproduct collaboration competent authority ultimately dispose chemical compliance current legislation waste past lack knowhow appro priate technical resource mean landfill dump solely responsible contami disposal method choice approach nate site landfill promptly conduct governed legislation result investigation take necessary remediation local authority suitable plot land measure example number contami available charge joint use number nate site originate company prior company acquisition roche remediate conver sely roche continue assume responsibility improve knowledge geological characteristic cost necessary remediation contaminate negative experience leak earth formation site landfill arise connection vitamin lead discontinuation landfill dis division sell bear cost posal chemical waste contaminate site sub relate action sizeable reserve ject increase monitor thorough examination set aside purpose order evaluate associate risk initiate step require containment remediation case landfill site share compa site question ny collaboration seek party concern order come solution acceptable roche pharmaceutical com pany relatively low volume chemical produc tion total quantities chemical waste share accept responsibility waste deposit deposit common landfill site rule small roche site landfill method disposal widespread time base relevant legal requirement business report safety health environmental protection non halogenate voc halogenate voc total voc x total inorganic wastewater organic carbon load measure total organic carbon toc wastewater treatment total metric ton discharge addition heavy metal discharge wastewater amount metric ton business report atmospheric emission metric ton year emission water air emission roche responsible metric ton inorganic emission form sulphur dioxide nitrogen oxide x substance result ofincineration process energy generationair emission soot parti culate dust come metric tonsemission volatile organic compound voc come metric tonsofwhich contain halogen toc metric tonsyear heavy metal kgyearwater consumption report water consumption roche base gri water protocol million metric ton ofwater consumediewent product vaporise cool air con ditioning system million metric ton ofwaste water chemical production purify wastewater treatment plant million metric ton represent water cool system return receive water thor ough analysis purification special chemical halogenate solvent metric ton year year review total metric ton halogenate solvent roche production facility laboratory methylene chloride account great ofthis total production ofthe active substance aids drug fuzeon account half total high consumption report reflect increase production volume chloroform small quantity laboratory compliance group directive roche affiliate supply figure quantity use substance thata precursor substance chemical weaponsdrug narcoticsare subject international regulation quantity report remain consistently low level num ber year compound manufacture roche product sub stance sell party safety health environmental protection water consumption million cubic metre year roche group withdrawal source purify treatment plant return receive water consumption business report safety health environmental protection business report ve get independence business report selfmonitore let patient life age alexander bcker nearly die school trip young german collapse rush hospital doctor discover meningitis cerebral hemorrhagealexander survive speech severely impairedand episode leave require lifelong treatment bloodthinning anticoagulant mean report regularly doctor therapy monitor alexander quickly overcome speech impairment train social care provider work predominantly people disabilitiestwo year ago regain old independence thank device s scarcely big cell phone coaguchek salexander able monitor anticoagulant therapy eliminate need weekly trip doctor year alexander go ninemonth roundtheworld trip take united statesaustralia new zealand japantravelling girlfriend companion trip possible placehis coaguchek monitor patient anticoagulant monitor coagulation status closely dose right level time require trip hospital doctor office device like coaguchek give patient independence enable monitor treat ment business report assurance assurance independent assurance report roche tional framework standard assurance engage group sustainability reporting ment approve december interna tional auditing assurance standard board iaasb roche corporate sustainability committee planned perform evidencegathering engage provide assurance procedure obtain basis conclusion sustainability report roche accordance international standard consolidated subsidiary exclude chugai assurance engagement isae assurance genentech group year end engagement audits review december perform evidence historical information approve december gathering procedure jointly refer iaasb subject matter key figure table entitle scope evidencegathering procedure important key figureson select social dimension information assess roche staff apply group internal social dataand sustainability report guideline site level management report prepara sample production site cover tion ofthe report figure pharmaceutical diagnostic division test effectiveness ofthe internal sustainability evaluate subject matter reporting system collect datum follow criterion evaluation criterion des social data group site crib observe compliance group internal sus roche group internal sustainability repor tainability report guideline select site te guideline respect responsible care healthsafety environmental reporting perform specific procedure checkon sample guideline publish european chemical basisthe data social datum industry council cefic sustainability report guideline publish evidencegathering procedure include global reporting initiative gri follow work procedure datum visit select site austria south africa social data preparedcollate aggregated turkey internallyand interview responsible stafffor datum collec control environment accuracy tion sustainability report site completeness ofthe data social datum visit group level statement read conjunction assess datum consolidation process inherent limitation ofaccuracy complete group level ness sustainability dataas connection read perform test ofthe relevant doc roche group internal reporting guideline umentation sample basis include group explain scope reporting policy management report structure documentation system collectana lyze aggregate report datum social roche group responsible subject dataand matter evaluation criterion perform test sample basis evidence support select datum social datum responsibility report internal regard report datum aggregation report processesdataand key figure social select site group levelhowever dimension base evidencega perform site visit chugai thering procedure accordance interna genentech business report assurance opinion roche group internal sustainability report guideline apply properly select site internal reporting system collect datum function designedand social dimension reporting provide appropriate basis disclosure social dimension information material respect base evaluation criterion base work describe reportnothing come attention cause believe procedure data social dimension information prepare collate aggregated control environ ment select site base establish accept measurement analytical method fair picture ofthe social diman sion performancein material respectsbase evaluation criterion pricewaterhousecoopers ag dr thomas scheiwiller jrg hutter zurich january business report track record outlook track record outlook objective goal target onwards achievement general remain tier increase internal external remain quartile renew inclusion transparency sustainability awareness improve posi index rating ftsegood djsi relate activity tion external investigation healthcare sector new website launch revise website base quarter stakeholder feedback sustainability topic inte expansion communication grate overall activity sustainability communication strategy internally externally sustainability include topic key internal corporate event establish roche business identification driver establish implement workshop hold member case sustainability business case monitoring process corporate measuring document business case divisional function identify appropriate kpis define set relevant key key area performance indicator kpi integrate operation section annual report sustain ability report form single business review ethic governance responsible management strengthen business ethic increase awareness high participation rate publication roche intranet awareness adherence roche corpo new elearning tool internet site roche rate principle roche roche code conduct corporate principle directive guideline incident roche directive guide regulation line policy regulation form roche code conduct form roche code conduct development new elearning tool ensure high standard independent external body discussion controversial establishment clinical relation human subject review escalate ethical political ethical topic research ethical advisory research create issue clinical research ethi inclusion data group creag transparency regard cal advisory group creag phase iiiv trial establish clinical trial pro clinical trial recognise lead product market tocol registry result clinical trial protocol registry october database trial register result database continue implementation new future retrospective contract new contract supply chain policy contract align incorporate new policy incorporate roche supplier supply chain policy policy coordinate social environmental alignment risk establishment clear pro responsibility assessment ethical risk assessment cedure assess risk risk define identification management group risk report process allocate rigorous management system focus risk assessment risk reduction measure audits business report track record outlook objective goal target onwards achievement ensure appropriate respon global coordinator system continuation audits revise animal welfare paper sible use animal resource introducedimplemente documentation global coordinator animal site adjustment process welfare identify site aaalac accreditation proof accreditation roche research site sustainability website conduct animal test contribution society develop new health solution produce medically differenti number new innovative key innovative launch unsolved health problem ate product product launch avastin high medical need class good class herceptin tarceva bonvivaboniva amplichip cyp improve access healthcare recognise quartile monitor pricing clinical trial policy develop develop company ensure access improve website develop country country healthcare documentsbrochure subsaharan africa improve transparency rating reduction pricing roche activity area activity tiere pricing tamiflu corporate policyposition formal csr policy internally externally review process initiate corporate responsibility csr establish csr policy philanthropy continuously update report csr activity sustainability website update internal action plan regular transparent reporting stakeholder dialogue improve systematic identification key stake good result external publish list membership stakeholder dialogue holder establish rating key partner web communication channel establishment agenda stakeholder survey perform provide consistent defining responsibility condition create collec timely communication continuous reporting ting datum ngo contact stakeholder dialogue website value employee improve position recognise tier good result peer review numerous award employer choice employer industry relevant award science fortune healthcare industry maintain high level rela low rate regret loss tionship company corporate culture business report track record outlook objective goal target onwards achievement safety health environmental protection reduce accident rate roche accident rate rar rar reduction vs reduce absence rate incl hemployee illness home accident reduction vs reduce energy consumption gjemployee reduction vs improve total ecobalance pointsemployee improvement vs relevant fine fine relevant fine chf reduce ghg emission co equivalentssale reduction vs reduce voc emission tonne vocsale reduction vs develop strategy position public position key position contaminate site key topic relate topic public interest issue matter business report key performance indicator key performance indicator economic business performance sale continue operation chf million ebitda continue operation chf million operating profit exceptional item chf million net income chf million core earning share diluted chf research development chf millions research development sale contact stakeholder dividend distribute chf million taxis pay chf million personnel cost chf million patient participate clinical trial available patient benefit donation available commitment employee newly create position number employee woman percentage woman management position fluctuation number training hour employee percentage country affiliate local general manager safety health environmental protection investment millions swiss franc operating cost million franc workrelate accident million work hour workday lose workrelate accident occupational illness million work hour workday lose occupational illness workrelate accident million work hour contractor firm total energy consumption tjyear co tyear tyear x tyear vocs tyear particulate matter tyear water consumption million cubic meter year toc tyear heavy metal tyear chemical waste tyear business report gri reference list gri reference list vision strategy reportremark statement organisation vision cid page strategy contribution sustainable development statement ceo cid profile organisational profile reporting organisation cid cid major product andor service cid cid page operational structure organisation cid cid description major division cid operating company subsidiarie joint venture country organisation operation locate cid cid nature ownership legal form cid nature market serve cid cid page scale reporting organisation number employee cid cid product producedservice offer quantity volume cid net sale cid cid total capitalisation break term debt equity cid addition report organisation encourage provide additional information value add cid total asset cid breakdown follow salesrevenue countriesregion percent cid accord region detail total revenue major product andor identify services cid product high sale page cost countryregion cid employee countryregion cid cid list stakeholder key attribute cid relationship report organisation report scope contact person report include email web address cid reporting period eg fiscalcalendar year information provide cid date recent previous report cid boundary report specific limitation scope cid significant change size structure ownership cid cid productsservice occur previous report basis report joint venture partially own subsidiary cid base cefic require parameter show lease facility outsource operation situation significantly affect comparability period period andor reporting organisation explanation nature effect restatement information cid provide early report reason restatement report profile decision apply gri principle cid protocol preparation report criteriadefinition accounting economic cid environmental social cost benefit significant change previous year cid cid measurement method apply key economic environmental social information policy internal practice enhance cid provide assurance accuracy completeness reliability place sustainability report policy current practice regard cid provide independent assurance report mean report user obtain additional information cid report economic environmental social aspect organisation activity include facilityspecific information available business report gri reference list governance structure management system reportremark structure governance governance structure organisation cid cid page percentage board director independent cid cid nonexecutive director process determine expertise board member need guide cid cid strategic direction organisation include issue relate environmental social risk opportunitie boardlevel process oversee organisation identification cid page management economic environmental social risk opportunitie linkage executive compensation achievement cid cid organisation financial nonfinancial goal eg environmental performance labour practice organisational structure key individual responsible oversight cid cid implementation audit economic environmental social relate policy mission value statement internally develop code cid page conduct principle police relevant economic environmental social performance status implementation mechanism shareholder provide recommendation cid cid direction board director stakeholder engagement basis identification selection major stakeholder cid approach stakeholder consultation report cid term frequency consultation type stakeholder group type information generate stakeholder consultation cid use information result stakeholder engagement cid overarch policy management system explanation precautionary approach cid principle address organisation externally develop voluntary economic environmental cid page social charter set principle initiative organisation subscribe endorse principal membership industry business association cid andor nationalinternational advocacy organisation policy andor system manage upstream downstream impact include supply chain management pertain outsource cid supplier environmental social performance product service stewardship initiative cid reporting organisation approach manage indirect economic cid environmental social impact result activity major decision report period cid location change operation programme procedure pertain economic environmental social performance include discussion priority target set cid major programme improve performance cid internal communication training cid performance monitor cid internal external auditing cid page senior management review cid status certification pertain economic environmental cid social management system gri content index table identify location element gri report cid content section indicator business report gri reference list economic performance indicator reportremark customer ec net sale cid cid ec geographic breakdown market cid cid page supplier ec cost good material service purchase cid ec percentage contract pay accordance cid principal contract carry agree term accord agree term employee ec total payroll benefit cid cid capital provider ec distribution provider capital cid ec increasedecrease retain earning end period cid public sector ec total sum taxis type break country cid cid total income taxis show broken country ec subsidy receive cid ec donation cid roche currently issue global figure limit significance environmental performance indicator material en total material water type cid production individual pharmaceutical substance take place completely different synthesis different place different time figure continuity value estimation environmental performance en percentage material waste cid remark en energy en direct energy use cid en indirect energy use cid en initiative increase energy efficiency cid page en indirect energy use cid water en total water use cid biodiversity en biodiversityrich habitat cid relevant roche business en impact biodiversity cid ecotoxicological material datum intermediate end product prepare publish report emission effluent waste en greenhouse gas emission cid page en use emission ozonedeplete substance cid en significant air emission typen cid x en total waste cid en significant discharge water type cid en significant spill chemical oil fuel cid product service en significant environmental impact cid environmental risk assessment principal product service prepare active substance publish report en recyclable product cid valorise byproduct recycle solvent compliance en fine noncompliance cid en total environmental expenditure type cid social performance indicator employment la workforce cid la net employment creation average turnover cid page labourmanagement relation la percentage employee represent cid la policy procedure involve information cid consultation negotiation employee change business report gri reference list health safety reportremark la occupational accident disease cid la health safety committee cid la key figure injury lose day absentee rate cid page workrelate fatality la description policy programme hivaids cid wwwrochecomhomesustainabilitysussoc sussoccommhtm training education la average hour training year employee cid diversity opportunity la equal opportunity policy programme cid la composition senior management corporate governance body cid cid page include board director la employee benefit cid cid cid locally arrange accord performance local business human right strategy management hr prevention discrimination business activity cid cid procedure deal human right hr human right investment procurement decision cid cid hr human right supply chain cid cid page nondiscrimination hr prevention discrimination business activity cid cid freedom association collective bargaining hr principle freedom association policy cid cid child labour hr principle exclusion child labour cid cid force compulsory labour hr guideline prevention force compulsory labour cid cid social guideline communitiescompanie description policy manage impact community area cid general guideline define locally affect activity description proceduresprogramme local company guideline address issue include monitor system result monitor award receive relevant social ethical cid environmental performance bribery corruption guideline address bribery corruption cid political support guideline manage political lobbying cid general guideline contribution direct local arrangement competition pricing court decision pertain antitrust monopoly regulation cid guideline prevention anticompetitive behaviour cid product responsibility consumer health safety pr guideline preservation customer health safety cid principle cover pharma ceutical industry great extent national international law guideline product service pr guideline product information label cid principle cover pharma ceutical industry great extent national international law guideline respect privacy pr guideline consumer privacy cid principle cover pharmaceuti cal industry great extent national international law guideline indicator detailed datum report indicator cover report detailed datum fully available indicator apply roche datum submit publish report datum available find finance report material violation business report sale manufacturing overview switzerland czech republic argentina denmark australia dominican republic austria ecuador bangladesh el salvador belgium estonia bermuda finland brazil france canada germany chile great britain china greece colombia guatemala costa rica guernsey business report roche global market presence roche global market presence research development service finance toll manufacture party honduras netherlands singapore hungary new zealand slovenia india nicaragua south africa indonesia norway south korea ireland pakistan spain italy panama sweden japan peru taiwan latvia philippine thailand lithuania poland turkey luxembourg portugal uruguay malaysia romania usa mexico russia venezuela morocco serbiaand montenegro business report publish cautionary statement forward fhoffmannla roche ltd look statement baselswitzerland annual report contain certain forwardlook tel ing statement forwardlooke statement fax identify word believe expect anticipate project intend media office seek estimate future similar expression corporate communication discussion thing strategy baselswitzerland goal plan intention factor tel cause actual result differ materially future fax reflect forwardlooke statement contain annual report investor relation pricing product initiative competitor baselswitzerland legislative regulatory development tel economic condition delay inability fax obtain regulatory approval bring prod uct market fluctuation currency world wide web exchange rate general financial market condi httpwwwrochecom tion uncertaintie discovery develop ment marketing new product new use corporate sustainability committee exist product include limitation pierre jaccoudchair negative result ofclinical trial research project tel unexpected sideeffect pipeline market emailpierrejaccoudrochecom product increase government pricing pre sure interruption production loss order publication orinability obtain adequate protection intel tel lectual property right litigation loss fax key executive employeesand adverse emailbaselwebmasterrochecom publicity news coverage statement earning share growth profit forecast inter prete mean roche earning earning share subsequent period necessarily match exceed historical publish earning earning share ofroche annual general meeting february trademark mention enjoy legal protection roche annual report publish german original language english print nonchloride bleach paper roche annual report issue f hoffmannla roche ltd basel corporate communication business report